‫ﻗﺎﺋﻤﺔ اﻷدوﻳﺔ اﻷﺳﺎﺳﻴﺔ‬

‫اﻟﻨﻤﻮذﺟﻴﺔ ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ‬

‫اﻟﻌﺎﻟﻤﻴﺔ‬
‫ﻗﺎﺋﻤﺔ وﻳﻜﻴﻤﻴﺪﻳﺎ‬

‫ﻳُ ﺼﺎدف ﻋﺎم ‪ 2017‬اﻟﺬﻛﺮى اﻷرﺑﻌﻴﻦ ﻟﻘﺎﺋﻤﺔ اﻷدوﻳﺔ اﻷﺳﺎﺳﻴﺔ‬

‫اﻟﻨﻤﻮذﺟﻴﺔ ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‪.‬‬
‫ﻗﺎﺋﻤﺔ اﻷدوﻳﺔ اﻷﺳﺎﺳﻴﺔ اﻟﻨﻤﻮذﺟﻴﺔ ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ‬
‫اﻟﻌﺎﻟﻤﻴﺔ]‪) [1‬ﺑﺎﻹﻧﺠﻠﻴﺰﻳﺔ‪WHO Model List of :‬‬
‫‪ (Essential Medicines‬وﺗﺪﻋﻰ اﺧﺘﺼﺎ ًرا ‪،EML‬‬
‫ﻫﻲ ﻗﺎﺋﻤﺔ ﻧﺸﺮﺗﻬﺎ ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‪ ،‬وﺗﺤﺘﻮي‬
‫أﻫﻢ‬
‫ﺗﻠﺒﻴﺔ ِ‬
‫ِ‬ ‫ً‬
‫وأﻣﺎﻧﺎ ﻓﻲ‬ ‫ً‬
‫ﻓﻌﺎﻟﻴﺔ‬ ‫اﻷﻛﺜﺮ‬ ‫اﻷدوﻳﺔ‬
‫ِ‬ ‫ﻋﻠﻰ‬
‫ِ‬
‫ُ‬
‫ﺴﺘﻌﻤﻞ ﻫﺬه‬‫اﻟﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ‪ُ .‬ﺗ‬
‫ِ‬ ‫ﻧﻈﺎم‬
‫ِ‬ ‫اﺣﺘﻴﺎﺟﺎت‬
‫ِ‬
‫ﻗﻮاﺋﻢ‬
‫َ‬ ‫ﺗﻄﻮﻳﺮ‬
‫ِ‬ ‫ﻟﻠﻤﺴﺎﻋﺪة ﻋﻠﻰ‬
‫ِ‬ ‫اﻟﺪول‬
‫ِ‬ ‫ﻛﺜﻴﺮا ﻓﻲ‬
‫ً‬ ‫اﻟﻘﺎﺋﻤﺔ‬
‫ﻣﺤﻠﻴﺔ ﻟﻸدوﻳﺔ اﻷﺳﺎﺳﻴﺔ‪ُ [2].‬‬
‫ﻣﻨﺬ ﻋﺎم ‪ ،2016‬ﻗﺎﻣﺖ‬ ‫ٍ‬
‫ﻣﺤﻠﻴﺔ وﻃﻨﻴﺔ‬
‫ٍ‬ ‫ﻗﻮاﺋﻢ‬
‫َ‬ ‫ﺑﺈﻧﺸﺎء‬
‫ِ‬ ‫‪ 156‬دوﻟﺔ ﻋﻠﻰ اﻷﻗﻞ‬
‫ﻟﻸدوﻳﺔ اﻷﺳﺎﺳﻴﺔ ُﻣﻌﺘﻤﺪ ًة ﻋﻠﻰ اﻟﻘﺎﺋﻤﺔ اﻟﻨﻤﻮذﺟﻴﺔ‬
‫ِ‬
‫ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‪ [3]،‬وﺗﺸﻤﻞ ً‬
‫دوﻻ ُﻣﺘﻘﺪﻣﺔ‬
‫ﻧﺎﻣﻴﺔ‪[2].‬‬ ‫واﺧﺮى‬

‫أﺳﺎﺳﻴﺔ واﺧﺮى‬
‫ﺗﻜﻤﻴﻠﻴﺔ‪[4].‬‬
‫ٍ‬ ‫ﻋﻨﺎﺻﺮ‬
‫َ‬ ‫ُ‬
‫اﻟﻘﺎﺋﻤﺔ إﻟﻰ‬ ‫ُﺗ َ‬
‫ﻘﺴ ُﻢ‬
‫اﻷﻛﺜﺮ ﻓﻌﺎﻟﻴﺔ ﻣﻦ‬
‫ُ‬ ‫ُﺗﻌﺘﺒﺮ اﻟﻌﻨﺎﺻﺮ اﻷﺳﺎﺳﻴﺔ اﻟﺨﻴﺎرات‬
‫ﻤﻜﻦ‬
‫ﺣﻴﺚ اﻟﺘﻜﻠﻔﺔ ﻟﻠﻤﺸﺎﻛﻞ اﻟﺼﺤﻴﺔ اﻟﺮﺋﻴﺴﻴﺔ وﻳُ ُ‬
 ‫ﻣﻮارد اﻟﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ اﻹﺿﺎﻓﻴﺔ‬
‫ِ‬ ‫ﻇﻞ‬
‫اﺳﺘﺨﺪاﻣﻬﺎ ﻓﻲ ِ‬
‫ﺗﻤﺘﻠﻚ ﻧﺴﺒﺔ‬
‫ُ‬ ‫اﻟﻘﻠﻴﻠﺔ‪ [4]،‬أﻣﺎ اﻟﻌﻨﺎﺻﺮ اﻟﺘﻜﻤﻴﻠﻴﺔ ﻓﻬﻲ إﻣﺎ‬
‫ﺗﺘﻄﻠﺐ ﺑﻨﻴﺔ ﺗﺤﺘﻴﺔ إﺿﺎﻓﻴﺔ‬
‫ُ‬ ‫ﺗﻜﻠﻔﺔ‪-‬ﻓﺎﺋﺪة ُﻣﻨﺨﻔﻀﺔ‪ ،‬أو‬
‫ﺑﺸﻜﻞ ﺧﺎص أو‬
‫ٍ‬ ‫ﺑﻴﻦ‬
‫ﻣﺜﻞ ﻣﻘﺪﻣﻲ رﻋﺎﻳﺔ ﺻﺤﻴﺔ ُﻣﺪر َ‬
‫ﻣﻌﺪات ﺗﺸﺨﻴﺺ‪ [4].‬ﺣﻮاﻟﻲ ‪ %25‬ﻣﻦ اﻟﻌﻨﺎﺻﺮ ﻫﻲ ﻓﻲ‬
‫ِ‬
‫ﻨﺎﻟﻚ أدوﻳﺔ ُﻣﺪرﺟﺔ ﺿﻤﻦ‬
‫وﻫ َ‬ ‫اﻟﻘﺎﺋﻤﺔ اﻟﺘﻜﻤﻴﻠﻴﺔ‪ُ [5]،‬‬
‫اﻟﻘﺎ ِﺋﻤﺘﻴﻦ‪ [6].‬ﺑﺎﻟﺮﻏﻢ ﻣﻦ أن ُﻣﻌﻈﻢ اﻷدوﻳﺔ اﻟﻤﺪرﺟﺔ ﻓﻲ‬
‫ﻛﺪواء ﺟﻨﻴﺲ‪ ،‬إﻻ أﻧﻬﺎ َﺗﺨﻀﻊ ﻟﺒﺮاءة‬
‫ٍ‬ ‫اﻟﻘﺎﺋﻤﺔ ﺗﺘﻮاﻓﺮ‬
‫إدراﺟﻬﺎ‪[7].‬‬ ‫اﻻﺧﺘﺮاع وﻫﺬا ﻻ ﻳﺴﺘﺒﻌﺪُ‬

‫ُ‬
‫ﺣﻴﺚ ﺗﻀﻤﻨﺖ ‪212‬‬ ‫ُﻧﺸﺮت ُ‬
‫أول ﻗﺎﺋﻤﺔ ﻓﻲ ﻋﺎم ‪1977‬‬
‫ﺑﺘﺤﺪﻳﺚ‬
‫ِ‬ ‫دواء‪ [8][2]،‬وﺗﻘﻮم ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‬
‫ً‬
‫اﻟﻘﺎﺋﻤﺔ ﻛﻞ ﺳﻨﺘﻴﻦ‪ُ [9].‬ﻧﺸﺮت اﻟﻘﺎﺋﻤﺔ اﻟﺮاﺑﻌﺔ ﻋﺸﺮة ﻓﻲ‬
‫دواء‪ [10]،‬وﻓﻲ ﻋﺎم ‪2015‬‬
‫ً‬ ‫ﻋﺎم ‪ 2005‬وﺗﻀﻤﻨﺖ ‪306‬‬
‫ُ‬
‫ﺣﻴﺚ اﺣﺘﻮت ﻋﻠﻰ‬ ‫ُﻧﺸﺮت اﻟﻨﺴﺨﺔ اﻟﺘﺎﺳﻌﺔ ﻋﺸﺮة‬
‫دواء‪ُ [9].‬ﻧﺸﺮت اﻟﻨﺴﺨﺔ اﻟﻌﺸﺮﻳﻦ ﻓﻲ ﻋﺎم ‪،2017‬‬
‫ً‬ ‫‪410‬‬
‫و َﺗ ُﻀﻢ ‪ 433‬دواء‪ [12][11].‬ﺗﺤﺘﻮي اﻟﻘﻮاﺋﻢ اﻟﻤﺤﻠﻴﺔ ﻋﻠﻰ‬
‫دواء‪[5].‬‬ ‫ﻣﺎ ﺑﻴﻦ ‪580-334‬‬

‫ﻋﺎﻣﺎ‬
‫ﺳﻦ ‪ً 12‬‬ ‫َ‬ ‫ٌ‬ ‫ا ْﻧ ِﺸﺌﺖ‬
‫ﺗﺤﺖ ِ‬ ‫ﻗﺎﺋﻤﺔ ُﻣﻨﻔﺼﻠﺔ ﻟﻸﻃﻔﺎل‬
‫و ُﺗﻌﺮف ﺑﺎﺳﻢ ﻗﺎﺋﻤﺔ اﻷدوﻳﺔ اﻷﺳﺎﺳﻴﺔ اﻟﻨﻤﻮذﺟﻴﺔ‬
‫ُ‬
‫ﺣﻴﺚ‬ ‫ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ اﻟﺨﺎﺻﺔ ﺑﺎﻷﻃﻔﺎل‪،‬‬
‫اﻟﺴﺎدﺳﺔ‪[13][9]،‬‬
‫أﻧﺸﺌﺖ ﻋﺎم ‪ 2007‬ﻓﻲ ﻧﺴﺨﺘﻬﺎ‬ ‫ِ‬
‫ﺑﺸﻜﻞ ﻣﻨﻈﻢ‬ ‫اﻷﻃﻔﺎل‬ ‫اﺣﺘﻴﺎﺟﺎت‬
‫ِ‬ ‫ﻋﻠﻰ‬ ‫ﻟﻠﺘﺄﻛﻴﺪ‬ ‫ُ‬
‫وﺗﻬﺪف‬
‫ٍ‬
‫ﺗﺮﻛﻴﺒﺎت ُﻣﻨﺎﺳﺒﺔ‪ [15][14].‬ﺟﻤﻴﻊ اﻷدوﻳﺔ ﻓﻲ‬
‫ٍ‬ ‫ﺗﻮاﻓﺮ‬
‫ِ‬ ‫ﻣﺜﻞ‬
‫ﻗﺎﺋﻤﺔ اﻷﻃﻔﺎل ُﻣﻀﻤﻨﺔ ﻓﻲ اﻟﻘﺎﺋﻤﺔ اﻟﺮﺋﻴﺴﻴﺔ‪ [16].‬ﺗﺮﺗﻜﺰ‬
‫اﻟﻘﺎﺋﻤﺔ واﻟﻤﻼﺣﻈﺎت ﻋﻠﻰ اﻟﻄﺒﻌﺔ اﻟﺘﺎﺳﻌﺔ ﻋﺸﺮة‬
‫واﻟﻌﺸﺮﻳﻦ ﻣﻦ اﻟﻘﺎﺋﻤﺔ اﻟﺮﺋﻴﺴﻴﺔ‪ [11][4]،‬أﻣﺎ أﻟﻔﺎ ﻓﻬﻲ‬
‫ُﺗﺸﻴﺮ إﻟﻰ أن اﻟﺪواء ﺿﻤﻦ اﻟﻘﺎﺋﻤﺔ اﻟﺘﻜﻤﻴﻠﻴﺔ ﻓﻘﻂ‪[4].‬‬
‫ُ‬

‫ﻣﺨﺪرات‬
‫اﻟﻤﺨﺪرات اﻟﻌﺎﻣﺔ واﻷﻛﺴﺠﻴﻦ‬
 ‫أدوﻳﺔ اﺳﺘﻨﺸﺎﻗﻴﺔ‬

‫ﻫﺎﻟﻮﺛﺎن‬
‫آﻳﺰوﻓﻠﻮران‬
‫أﻛﺴﻴﺪ اﻟﻨﻴﺘﺮوز‬
‫اﻟﻌﻼج ﺑﺎﻷﻛﺴﺠﻴﻦ‬

‫أدوﻳﺔ ﻗﺎﺑﻠﺔ ﻟﻠﺤﻘﻦ‬

‫ﻛﻴﺘﺎﻣﻴﻦ‬
‫ﺑﺮوﺑﻮﻓﻮل]ﻣﻼﺣﻈﺔ ‪[1‬‬

‫اﻟﻤﺨﺪرات اﻟﻤﻮﺿﻌﻴﺔ‬

‫ﺑﻮﺑﻴﻔﺎﻛﺎﻳﻴﻦ‬
‫ﻟﻴﺪوﻛﺎﺋﻴﻦ‬
‫ﻟﻴﺪوﻛﺎﺋﻴﻦ‬
‫إﻓﻴﺪرﻳﻦ‪) α‬ﻟﻴﺲ ُﻣﺨﺪر ﻣﻮﺿﻌﻲ‪ ،‬وﻟﻜﻦ ﻳﺘﻮاﺟﺪ‬
‫ﻤﻨﻊ اﻧﺨﻔﺎض ﺿﻐﻂ اﻟﺪم‬
‫ﺿﻤﻦ ﻫﺬه اﻟﻘﺎﺋﻤﺔ ِﻟ ِ‬
‫اﻟﻤﺮﺗﺒﻂ ﺑﺎﻟﺘﺨﺪﻳﺮ اﻟﻨﺨﺎﻋﻲ ﺧﻼل اﻟﻮﻻدة اﻟﻘﻴﺼﺮﻳﺔ(‬
‫ُ‬

‫ﺨﺪرات‬
‫أدوﻳﺔ ﺳﺎﺑﻘﺔ ﻟﻠﺠﺮاﺣﺔ وﻣُ ِ‬
‫اﻹﺟﺮاءات ﻗﺼﻴﺮة اﻟﻤُ ﺪة‬

‫أﺗﺮوﺑﻴﻦ‬
‫ﻣﻴﺪازوﻻم‬
‫ﻣﻮرﻓﻴﻦ‬

‫أدوﻳﺔ اﻷﻟﻢ واﻟﻌﻨﺎﻳﺔ اﻟﺘﻠﻄﻴﻔﻴﺔ‬

‫أدوﻳﺔ ﻻأﻓﻴﻮﻧﻴﺔ ﻻﺳﺘﻴﺮوﻳﺪﻳﺔ ﻣﻀﺎدة‬
‫ﻟﻼﻟﺘﻬﺎب‬

‫ﺻﻴﻐﺔ ﻫﻴﻜﻠﻴﺔ ﻟﻠﺘﺮﻛﻴﺐ اﻟﻜﻴﻤﻴﺎﺋﻲ ﻟﻸﺳﺒﺮﻳﻦ‬

 ‫ﺣﻤﺾ أﺳﻴﺘﻴﻞ ﺳﺎﻟﻴﺴﻴﻠﻴﻚ )أﺳﺒﺮﻳﻦ(‬
‫إﻳﺒﻮﺑﺮوﻓﻴﻦ‬
‫ﺑﺎراﺳﻴﺘﺎﻣﻮل]ﻣﻼﺣﻈﺔ ‪) [2‬أﺳﻴﺘﺎﻣﻴﻨﻮﻓﻴﻦ(‬

‫ﻣﺴﻜﻨﺎت أﻓﻴﻮﻧﻴﺔ‬

‫ﻛﻮدﻳﻦ‬
‫ﻓﻴﻨﺘﺎﻧﻴﻞ‬
‫ﻣﻮرﻓﻴﻦ]ﻣﻼﺣﻈﺔ ‪[3‬‬

‫ﻣﻴﺜﺎدون‪α‬‬

‫أدوﻳﺔ ﻟﻸﻋﺮاض اﻷﺧﺮى اﻟﺸﺎﺋﻌﺔ ﻓﻲ‬

‫اﻟﻌﻨﺎﻳﺔ اﻟﺘﻠﻄﻴﻔﻴﺔ‬

‫أﻣﻴﺘﺮﺑﺘﻴﻠﻴﻦ‬
‫ﺳﻴﻜﻠﻴﺰﻳﻦ‬
‫دﻳﻜﺴﺎﻣﻴﺘﺎزون‬
‫دﻳﺎزﻳﺒﺎم‬
 ‫دوﻛﻮﺳﺎت اﻟﺼﻮدﻳﻮم‬
‫ﻓﻠﻮﻛﺴﻴﺘﻴﻦ‬
‫ﻫﺎﻟﻮﺑﻴﺮﻳﺪول‬
‫ﺑﻮﺗﻴﻞ ﺳﻜﻮﺑﻮل أﻣﻴﻦ‬
‫ﻫﻴﻮﺳﻴﻦ‬
‫ﻻﻛﺘﻮﻟﻮز‬
‫ﻟﻮﺑﻴﺮاﻣﻴﺪ‬
‫ﻣﻴﺘﻮﻛﻠﻮﺑﺮاﻣﻴﺪ‬
‫ﻣﻴﺪازوﻻم‬
‫أوﻧﺪاﻧﺴﻴﺘﺮون‬
‫ﺳﻨﺎ‬

‫ﻣﻀﺎدات اﻟﺤﺴﺎﺳﻴﺔ واﻷدوﻳﺔ‬

‫اﻟﻤﺴﺘﺨﺪﻣﺔ ﻓﻲ ﺻﺪﻣﺔ اﻟﺤﺴﺎﺳﻴﺔ‬
‫اﻟﻤﻔﺮﻃﺔ‬
 ‫دﻳﻜﺴﺎﻣﻴﺘﺎزون‬
‫إﺑﻴﻨﻴﻔﺮﻳﻦ )أدرﻳﻨﺎﻟﻴﻦ(‬
‫ﻫﻴﺪروﻛﻮرﺗﻴﺰون‬
‫ﻟﻮراﺗﺎدﻳﻦ]ﻣﻼﺣﻈﺔ ‪[4‬‬

‫ﺑﺮﻳﺪﻧﻴﺰوﻟﻮن‬

‫اﻟﻤﺴﺘﺨﺪﻣﺔ‬
‫اﻟﺘﺮﻳﺎﻗﺎت واﻟﻤﻮاد اﻷﺧﺮى ُ‬
‫ﻓﻲ اﻟﺘﺴﻤﻢ‬
‫ﻻﻧﻮﻋﻴﺔ‬

‫ﻓﺤﻢ ﻣﻨﺸﻂ‬

‫ﻧﻮﻋﻴﺔ‬

‫أﺳﻴﺘﻴﻞ ﺳﻴﺴﺘﺌﻴﻦ‬
‫أﺗﺮوﺑﻴﻦ‬
‫ﻏﻠﻮﻛﻮﻧﺎت اﻟﻜﺎﻟﺴﻴﻮم‬
‫ﻛﻠﻮرﻳﺪ اﻟﻤﻴﺜﻴﻠﺜﻴﻮﻧﻴﻨﻴﻮم )أزرق اﻟﻤﻴﺜﻴﻠﻴﻦ(‬
‫ﻧﺎﻟﻮﻛﺴﻮن‬
‫ﺑﻨﻴﺴﻴﻼﻣﻴﻦ‬
‫زرﻗﺔ ﺑﺮوﺳﻴﺎ‬
‫ﻧﺘﺮﻳﺖ اﻟﺼﻮدﻳﻮم‬
‫ﺛﻴﻮﺳﻠﻔﺎت اﻟﺼﻮدﻳﻮم‬
‫دﻳﻔﻴﺮوﻛﺴﺎﻣﻴﻦ‪α‬‬

‫اﻟﻤﺮﻛﺎﺑﺮول‪α‬‬ ‫ﺛﻨﺎﺋﻲ‬
‫ﻓﻮﻣﺒﻴﺰول‪α‬‬

‫اﻟﺼﻮدﻳﺔ‪α‬‬ ‫إﻳﺪﻳﺘﺎت اﻟﻜﻠﺴﻴﻮم‬

‫ﺳﻜﺴﻴﻤﺮ‪α‬‬

‫ﻣﻀﺎدات اﻻﺧﺘﻼج‬
‫ﻛﺎرﺑﺎﻣﺎزﻳﺒﻴﻦ‬
‫دﻳﺎزﻳﺒﺎم‬
 ‫ﻻﻣﻮﺗﺮﻳﺠﻴﻦ‬
‫ﻟﻮرازﻳﺒﺎم‬
‫اﻟﻤﻐﻨﻴﺴﻴﻮم]ﻣﻼﺣﻈﺔ ‪[5‬‬ ‫ﻛﺒﺮﻳﺘﺎت‬
‫ﻣﻴﺪازوﻻم‬
‫ﻓﻴﻨﻮﺑﺎرﺑﻴﺘﺎل‬
‫ﻓﻴﻨﻴﺘﻮﻳﻦ‬
‫ﺣﻤﺾ اﻟﻔﺎﻟﺒﺮوﻳﻚ )ﻓﺎﻟﺒﺮوات اﻟﺼﻮدﻳﻮم(‬
‫إﻳﺜﻮﺳﻮﻛﺴﻴﻤﻴﺪ‪α‬‬

‫ﻣﻀﺎدات اﻟﻌﺪوى‬
‫ﻃﺎردات اﻟﺪﻳﺪان‬

‫ﻃﺎردات اﻟﺪﻳﺪان اﻟﻤﻌﻮﻳﺔ‬

‫ﻧﻤﻮذج ﻫﻴﻜﻠﻲ ﻟﻠﺘﺮﻛﻴﺐ اﻟﻜﻴﻤﺎﺋﻲ ﻟﻸﻟﺒﻴﻨﺪازول‬

‫أﻟﺒﻴﻨﺪازول‬
‫إﻳﻔﻴﺮﻣﻜﺘﻴﻦ‬
‫ﻟﻴﻔﺎﻣﻴﺰول‬
‫ﻣﻴﺒﻴﻨﺪازول‬
‫ﻧﻴﻜﻠﻮزاﻣﻴﺪ‬
‫ﺑﺮازﻳﻜﻮاﻧﺘﻴﻞ‬
‫ﺑﻴﺮاﻧﺘﻴﻞ‬

‫ﻣﻀﺎدات اﻟﻔﻴﻼرﻳﺎ‬

‫أﻟﺒﻴﻨﺪازول‬
‫ﺛﻨﺎﺋﻲ إﻳﺜﻴﻞ ﻛﺎرﺑﺎﻣﺎزﻳﻦ‬
‫إﻳﻔﻴﺮﻣﻜﺘﻴﻦ‬
‫ﻣﻀﺎدات اﻟﺒﻠﻬﺎرﺳﻴﺎت وﻣﻀﺎدات‬
‫اﻟﻤﻤﺴﻮدات اﻷﺧﺮى‬
 ‫ﺑﺮازﻳﻜﻮاﻧﺘﻴﻞ‬
‫ﺛﻼﺛﻲ اﻟﻜﻼﺑﻴﻨﺪازول‬
‫أوﻛﺴﺎﻣﻨﻴﻜﻮﻳﻦ‪α‬‬

‫ﻣﻀﺎدات ﺣﻴﻮﻳﺔ‬

‫أدوﻳﺔ ﺑﻴﺘﺎ ﻻﻛﺘﺎم‬

‫أﻣﻮﻛﺴﻴﺴﻴﻠﻴﻦ‬
‫أﻣﻮﻛﺴﻴﺴﻴﻠﻴﻦ‪/‬ﺣﻤﺾ اﻟﻜﻼﻓﻮﻻﻧﻴﻚ )أﻣﻮﻛﺴﻴﺴﻴﻠﻴﻦ‬
‫‪ +‬ﺣﻤﺾ اﻟﻜﻼﻓﻮﻟﻴﻨﻴﻚ(‬
‫أﻣﺒﻴﺴﻴﻠﻴﻦ‬
‫ﺑﻨﺰاﺛﻴﻦ ﺑﻨﺰﻳﻞ ﺑﻨﺴﻴﻠﻴﻦ‬
‫ﺑﻨﺰﻳﻞ ﺑﻨﺴﻴﻠﻴﻦ‬
‫ﺳﻴﻔﺎﻟﻜﺴﻴﻦ‬
‫ﺳﻴﻔﺎزوﻟﻴﻦ]ﻣﻼﺣﻈﺔ ‪[6‬‬

‫ﺳﻴﻔﻴﻜﺰﻳﻢ]ﻣﻼﺣﻈﺔ ‪[7‬‬
 ‫ﺳﻴﻔﻮﺗﺎﻛﺴﻴﻢ]ﻣﻼﺣﻈﺔ ‪[8‬‬

‫ﺳﻴﻔﺘﺮﻳﺎﻛﺴﻮن]ﻣﻼﺣﻈﺔ ‪[9‬‬

‫ﻛﻠﻮﻛﺴﺎﺳﻠﻴﻦ‬
‫ﻓﻴﻨﻮﻛﺴﻲ ﻣﻴﺜﻴﻞ ﺑﻨﺴﻴﻠﻴﻦ )ﺑﻨﺴﻠﻴﻦ ‪(V‬‬
‫ﺑﻴﺒﺮاﺳﻴﻠﻴﻦ‪/‬ﺗﺎزوﺑﺎﻛﺘﺎم‬
‫ﺑﻨﺴﻴﻠﻠﻴﻦ]ﻣﻼﺣﻈﺔ ‪[10‬‬ ‫ﺑﺮوﻛﺎﻳﻦ ﺑﻨﺰﻳﻞ‬
‫ﺳﻴﻔﺘﺎزﻳﺪﻳﻢ‪α‬‬

‫ﻣﻴﺮوﺑﻴﻨﻢ‪α‬‬

‫أزﺗﺮﻳﻮﻧﺎم‪α‬‬

‫اﻣﻴﺒﻴﻨﻴﻢ‪/‬ﺳﻴﻼﺳﺘﺎﺗﻴﻦ‪]α‬ﻣﻼﺣﻈﺔ ‪[11‬‬

‫ﻣﻀﺎدات ﺑﻜﺘﻴﺮﻳﺔ أﺧﺮى‬

‫أﻣﻴﻜﺎﺳﻴﻦ‬
‫أزﻳﺜﺮوﻣﺎﻳﺴﻴﻦ]ﻣﻼﺣﻈﺔ ‪[12‬‬

‫ﻛﻠﻮراﻣﻔﻴﻨﻴﻜﻮل‬
 ‫ﺳﻴﺒﺮوﻓﻠﻮﻛﺴﺎﺳﻴﻦ‬
‫ﻛﻼرﻳﺜﺮوﻣﻴﺴﻴﻦ]ﻣﻼﺣﻈﺔ ‪[13‬‬

‫ﻛﻠﻴﻨﺪاﻣﻴﺴﻴﻦ‬
‫دوﻛﺴﻴﺴﺎﻳﻜﻠﻴﻦ‬
‫إرﻳﺜﺮوﻣﻴﺴﻴﻦ‬
‫ﺟﻨﺘﺎﻣﻴﺴﻴﻦ‬
‫ﻣﺘﺮوﻧﻴﺪازول‬
‫ﻧﻴﺘﺮوﻓﻮراﻧﺘﻮﻳﻦ‬
‫ﺳﺒﻜﺘﻴﻨﻮﻣﻴﺴﻴﻦ‬
‫ﺗﺮﻳﻤﻴﺜﻮﺑﺮﻳﻢ‪/‬ﺳﻠﻔﺎﻣﻴﺜﻮﻛﺴﺎزول‬
‫ﺗﺮﻳﻤﻴﺜﻮﺑﺮﻳﻢ‬
‫ﻓﺎﻧﻜﻮﻣﻴﺴﻴﻦ‬

‫ﻣﻀﺎدات اﻟﺠﺬام‬

‫ﻛﻠﻮﻓﺎزﻳﻤﻴﻦ‬
 ‫داﺑﺴﻮن‬
‫رﻳﻔﺎﻣﺒﻴﺴﻴﻦ‬

‫ﻣﻀﺎدات اﻟﺴﻞ‬

‫ﺑﻠﻮرات ﻧﻘﻴﺔ ﻣﻦ اﻹﻳﺜﺎﻣﺒﻮﺗﻮل‬

‫إﻳﺜﺎﻣﺒﻮﺗﻮل‬
‫إﻳﺜﺎﻣﺒﻮﺗﻮل‪/‬آﻳﺰوﻧﻴﺎزﻳﺪ )إﻳﺜﺎﻣﺒﻮﺗﻮل ‪ +‬آﻳﺰوﻧﻴﺎزﻳﺪ(‬
‫إﻳﺜﺎﻣﺒﻮﺗﻮل‪/‬آﻳﺰوﻧﻴﺎزﻳﺪ‪/‬ﺑﻴﺮازﻳﻨﺎﻣﻴﺪ‪/‬رﻳﻔﺎﻣﺒﻴﺴﻴﻦ‬
‫)إﻳﺜﺎﻣﺒﻮﺗﻮل ‪ +‬آﻳﺰوﻧﻴﺎزﻳﺪ ‪ +‬ﺑﻴﺮازﻳﻨﺎﻣﻴﺪ ‪+‬‬
‫رﻳﻔﺎﻣﺒﻴﺴﻴﻦ(‬
‫إﻳﺜﺎﻣﺒﻮﺗﻮل‪/‬آﻳﺰوﻧﻴﺎزﻳﺪ‪/‬رﻳﻔﺎﻣﺒﻴﺴﻴﻦ )إﻳﺜﺎﻣﺒﻮﺗﻮل ‪+‬‬
‫آﻳﺰوﻧﻴﺎزﻳﺪ ‪ +‬رﻳﻔﺎﻣﺒﻴﺴﻴﻦ(‬
 ‫آﻳﺰوﻧﻴﺎزﻳﺪ‬
‫آﻳﺰوﻧﻴﺎزﻳﺪ‪/‬ﺑﻴﺮازﻳﻨﺎﻣﻴﺪ‪/‬رﻳﻔﺎﻣﺒﻴﺴﻴﻦ )آﻳﺰوﻧﻴﺎزﻳﺪ ‪+‬‬
‫ﺑﻴﺮازﻳﻨﺎﻣﻴﺪ ‪ +‬رﻳﻔﺎﻣﺒﻴﺴﻴﻦ(‬
‫آﻳﺰوﻧﻴﺎزﻳﺪ‪/‬رﻳﻔﺎﻣﺒﻴﺴﻴﻦ )آﻳﺰوﻧﻴﺎزﻳﺪ ‪+‬‬
‫رﻳﻔﺎﻣﺒﻴﺴﻴﻦ(‬
‫ﺑﻴﺮازﻳﻨﺎﻣﻴﺪ‬
‫رﻳﻔﺎﺑﻮﺗﻴﻦ]ﻣﻼﺣﻈﺔ ‪[14‬‬

‫رﻳﻔﺎﻣﺒﻴﺴﻴﻦ‬
‫رﻳﻔﺎﺑﻨﺘﻴﻦ]ﻣﻼﺣﻈﺔ ‪[15‬‬

‫أﻣﻴﻜﺎﺳﻴﻦ‪α‬‬

‫ﺑﻴﺪاﻛﻴﻠﻴﻦ‪α‬‬

‫ﻛﺎﺑﺮﻳﻮﻣﻴﺴﻴﻦ‪α‬‬

‫ﻛﻠﻮﻓﺎزﻳﻤﻴﻦ‪α‬‬

‫ﺳﻴﻜﻠﻮﺳﻴﺮﻳﻦ‪]α‬ﻣﻼﺣﻈﺔ ‪[16‬‬

‫ﻫﻮ‪α‬‬ ‫دﻳﻼﻣﺎﻧﻴﺪ‬
 ‫إﺛﻴﻮﻧﺎﻣﻴﺪ‪]α‬ﻣﻼﺣﻈﺔ ‪[17‬‬

‫‪αA‬‬ ‫ﻛﺎﻧﺎﻣﻴﺴﻴﻦ‬
‫ﻟﻴﻔﻮﻓﻠﻮﻛﺴﺎﺳﻴﻦ‪]α‬ﻣﻼﺣﻈﺔ ‪[18‬‬

‫ﻟﻨﺰوﻟﻴﺪ‪α‬‬

‫ﻣﻮﻛﺴﻴﻔﻠﻮﻛﺴﺎﺳﻴﻦ‬
‫اﻟﺴﺎﻟﻴﺴﻴﻠﻴﻚ‪α‬‬ ‫‪-4‬أﻣﻴﻨﻮ ﺣﻤﺾ‬
‫ﺳﺘﺮﺑﺘﻮﻣﻴﺴﻴﻦ‪α‬‬

‫ﻣﻀﺎدات اﻟﻔﻄﺮﻳﺎت‬

‫أﻣﻔﻮﺗﻴﺮﻳﺴﻴﻦ ب‬
‫ﻛﻠﻮﺗﺮﻳﻤﺎزول‬
‫ﻓﻠﻮﻛﻮﻧﺎزول‬
‫ﻓﻠﻮﺳﻴﺘﻮزﻳﻦ‬
‫ﻏﺮﻳﺴﻴﻮﻓﻮﻟﻔﻴﻦ‬
‫إﻳﺘﺮاﻛﻮﻧﺎزول‬
 ‫ﻧﻴﺴﺘﺎﺗﻴﻦ‬
‫ﻓﻮرﻳﻜﻮﻧﺎزول‬
‫اﻟﺒﻮﺗﺎﺳﻴﻮم‪α‬‬ ‫ﻳﻮدﻳﺪ‬

‫ﻣﻀﺎدات اﻟﻔﻴﺮوﺳﺎت‬

‫ﻣﻀﺎدات اﻟﻬﺮﺑﺲ‬

‫آﺳﻴﻜﻠﻮﻓﻴﺮ‬

‫ﻣﻀﺎدات اﻟﻔﻴﺮوﺳﺎت اﻟﻘﻬﻘﺮﻳﺔ‬

‫ﻣﺜﺒﻄﺎت اﻟﻨﺎﺳﺨﺔ اﻟﻌﻜﺴﻴﺔ ﻟﻠﻨﻮﻛﻠﻴﻮﺗﻴﺪ‪/‬‬

‫اﻟﻨﻮﻛﻠﻴﻮزﻳﺪ‬

‫أﺑﺎﻛﺎﻓﻴﺮ )‪(ABC‬‬
‫ﻻﻣﻴﻔﻮدﻳﻦ )‪(3TC‬‬
‫ﺗﻴﻨﻮﻓﻮﻓﻴﺮ )‪(TDF‬‬
‫زﻳﺪوﻓﻮدﻳﻦ )‪(ZDV or AZT‬‬
‫ﻣﺜﺒﻄﺎت اﻟﻨﺎﺳﺨﺔ اﻟﻌﻜﺴﻴﺔ ﻟﻼﻧﻮﻛﻠﻴﻮزﻳﺪ‬

‫إﻳﻔﺎﻓﻴﺮﻳﻨﺰ )‪(EGV or EFZ‬‬

‫ﻧﻴﻔﻴﺮاﺑﻴﻦ )‪(NVP‬‬

‫ﻣﺜﺒﻄﺎت اﻟﺒﺮوﺗﻴﺎز‬

‫ﻛﺒﺴﻮﻟﺘﻴﻦ أﺗﺎزاﻧﺎﻓﻴﺮ‬

‫أﺗﺎزاﻧﺎﻓﻴﺮ‬
‫أﺗﺎزاﻧﺎﻓﻴﺮ‪/‬رﻳﺘﻮﻧﺎﻓﻴﺮ‬
‫داروﻧﺎﻓﻴﺮ‬
‫ﻟﻮﺑﻴﻨﺎﻓﻴﺮ‪/‬رﻳﺘﻮﻧﺎﻓﻴﺮ )‪(LPV/r‬‬
‫رﻳﺘﻮﻧﺎﻓﻴﺮ‬
 ‫ﻣﺜﺒﻄﺎت اﻹﻧﺰﻳﻢ ﻣﺪﻣﺞ‬

‫دوﻟﻮﺗﻐﺮاﻓﻴﺮ‬
‫راﻟﺘﻐﺮاﻓﻴﺮ‬

‫ﻣﺮﻛﺒﺎت اﻟﺠﺮﻋﺔ اﻟﺜﺎﺑﺘﺔ‬

‫أﺑﺎﻛﺎﻓﻴﺮ‪/‬ﻻﻣﻴﻔﻮدﻳﻦ‬
‫إﻣﺘﺮﻳﺴﻴﺘﺎﺑﻴﻦ‪/‬ﺗﻴﻨﻮﻓﻮﻓﻴﺮ‪/‬إﻳﻔﺎﻓﻴﺮﻳﻨﺰ]ﻣﻼﺣﻈﺔ ‪[19‬‬

‫إﻳﻔﺎﻓﻴﺮﻳﻨﺰ‪/‬ﻻﻣﻴﻔﻮدﻳﻦ‪/‬ﺗﻴﻨﻮﻓﻮﻓﻴﺮ‬
‫ﺗﻴﻨﻮﻓﻮﻓﻴﺮ‪/‬إﻣﺘﺮﻳﺴﻴﺘﺎﺑﻴﻦ]ﻣﻼﺣﻈﺔ ‪[19‬‬

‫ﻻﻣﻴﻔﻮدﻳﻦ‪/‬ﻧﻴﻔﻴﺮاﺑﻴﻦ‪/‬زﻳﺪوﻓﻮدﻳﻦ‬
‫ﻻﻣﻴﻔﻮدﻳﻦ‪/‬زﻳﺪوﻓﻮدﻳﻦ‬
‫أدوﻳﺔ ﻟﻠﻮﻗﺎﻳﺔ ﻣﻦ اﻟﻌﺪوى اﻻﻧﺘﻬﺎزﻳﺔ‬
‫اﻟﻤﺮﺗﺒﻄﺔ ﺑﻔﻴﺮوس ﻧﻘﺺ اﻟﻤﻨﺎﻋﺔ اﻟﺒﺸﺮﻳﺔ‬

‫إﻳﺰوﻧﻴﺎزﻳﺪ‪/‬ﺑﻴﺮﻳﺪﻛﺴﻴﻦ‪/‬ﺳﻠﻔﺎﻣﻴﺜﻮﻛﺴﺎزول‪/‬‬
‫ﺗﺮﻳﻤﻴﺜﻮﺑﺮﻳﻢ‬
 ‫ﻣﻀﺎدات ﻓﻴﺮوﺳﻴﺔ اﺧﺮى‬

‫رﻳﺒﺎﻓﻴﺮﻳﻦ]ﻣﻼﺣﻈﺔ ‪[20‬‬

‫ﻓﺎل ﻗﺎﻧﺴﻴﻜﻠﻮﻓﻴﺮ‬
‫أوﺳﻴﻠﺘﺎﻣﻴﻔﻴﺮ‪]α‬ﻣﻼﺣﻈﺔ ‪[21‬‬

‫ﻣﻀﺎدات اﻟﺘﻬﺎب اﻟﻜﺒﺪ‬

‫أدوﻳﺔ اﻟﺘﻬﺎب اﻟﻜﺒﺪ ب‬

‫ﻣﺜﺒﻄﺎت اﻟﻨﺎﺳﺨﺔ اﻟﻌﻜﺴﻴﺔ ﻟﻠﻨﻮﻛﻠﻴﻮﺗﻴﺪ‪/‬اﻟﻨﻮﻛﻠﻴﻮزﻳﺪ‬

‫إﻧﺘﻴﻜﺎﻓﻴﺮ‬
‫ﺗﻴﻨﻮﻓﻮﻓﻴﺮ )‪(TDF‬‬

‫أدوﻳﺔ اﻟﺘﻬﺎب اﻟﻜﺒﺪ ج‬

‫ﻣﺜﺒﻄﺎت ﺑﻮﻟﻴﻤﻴﺮاز اﻟﻨﻮﻛﻠﻴﻮﺗﻴﺪ‬

‫ﺳﻮﻓﻮﺳﺒﻮﻓﻴﺮ‬
 ‫ﻣﺜﺒﻄﺎت اﻟﺒﺮوﺗﻴﺎز‬

‫ﺳﻴﻤﺒﺮﻳﻔﻴﺮ‬

‫ﻣﺜﺒﻄﺎت اﻟﺒﺮوﺗﻴﻦ اﻟﻼﺑﻨﻴﻮي ‪5A‬‬

‫داﻛﻼﺗﺎﺳﻔﻴﺮ‬

‫ﻣﺜﺒﻄﺎت ﺑﻮﻟﻴﻤﻴﺮاز اﻟﻼﻧﻮﻛﻠﻴﻮزﻳﺪ‬

‫داﺳﺎﺑﻮﻓﻴﺮ‬

‫ﻣﻀﺎدات ﻓﻴﺮوﺳﻴﺔ أﺧﺮى‬

‫رﻳﺒﺎﻓﻴﺮﻳﻦ]ﻣﻼﺣﻈﺔ ‪[22‬‬

‫ﺑﻴﻐﻨﺘﻴﺮﻓﻴﺮون – أﻟﻔﺎ – ‪2‬أ أو ﺑﻴﻐﻨﺘﻴﺮﻓﻴﺮون – أﻟﻔﺎ‬

‫‪2‬ب‪]α‬ﻣﻼﺣﻈﺔ ‪[23‬‬ ‫–‬

‫ﻣﺮﻛﺒﺎت اﻟﺠﺮﻋﺔ اﻟﺜﺎﺑﺘﺔ‬

‫ﻟﻴﺪﻳﺒﺎﺳﻔﻴﺮ‪/‬ﺳﻮﻓﻮﺳﺒﻮﻓﻴﺮ‬
 ‫أﻣﺒﻴﺘﺎﺳﻔﻴﺮ‪/‬ﺑﺎرﻳﺘﺎﺑﺮﻳﻔﻴﺮ‪/‬رﻳﺘﻮﻧﺎﻓﻴﺮ‬
‫ﻓﻠﺒﺎﺗﺎﺳﻔﻴﺮ‪/‬ﺳﻮﻓﻮﺳﺒﻮﻓﻴﺮ‬

‫ﻣﻀﺎدات اﻷوﻟﻴﺎت‬

‫ﻣﻀﺎدات أﻣﻴﺒﻴﺔ وﻣﻀﺎدات داء‬

‫اﻟﺠﻴﺎردﻳﺎت‬

‫دﻳﻠﻮﻛﺴﺎﻧﻴﺪ‬
‫ﻣﺘﺮوﻧﻴﺪازول‬

‫ﻣﻀﺎدات داء اﻟﻠﻴﺸﻤﺎﻧﻴﺎت‬

‫أﻣﻔﻮﺗﻴﺮﻳﺴﻴﻦ ب‬
‫ﻣﻴﻠﺘﻴﻔﻮﺳﻴﻦ‬
‫ﺑﺎروﻣﻮﻣﺎﻳﺴﻴﻦ‬
‫ﺳﺘﻴﺒﻮﺟﻠﻮﻛﻮﻧﺎت اﻟﺼﻮدﻳﻮم أو أﻧﺘﻴﻤﻮﻧﻴﺎت‬
‫اﻟﻤﻴﻐﻠﻮﻣﻴﻦ‬

‫ﻣﻀﺎدات اﻟﻤﻼرﻳﺎ‬
 ‫ﻟﻠﻤﻌﺎﻟﺠﺔ اﻟﺸﺎﻓﻴﺔ‬

‫أﻣﻮﻳﺎﻛﻮﻳﻦ]ﻣﻼﺣﻈﺔ ‪[24‬‬

‫أرﺗﻴﻤﻴﺜﺮ]ﻣﻼﺣﻈﺔ ‪[25‬‬

‫أرﺗﻴﻤﻴﺜﺮ‪/‬ﻟﻮﻣﻴﻔﺎﻧﺘﺮﻳﻦ]ﻣﻼﺣﻈﺔ ‪[26‬‬

‫أرﺗﻴﺴﻮﻧﺎت]ﻣﻼﺣﻈﺔ ‪[27‬‬

‫اﻷرﺗﻴﺴﻮﻧﺎت‪/‬أﻣﻮﻳﺎﻛﻮﻳﻦ]ﻣﻼﺣﻈﺔ ‪[28‬‬

‫أرﺗﻴﺴﻮﻧﺎت‪/‬ﻣﻔﻠﻮﻛﻮﻳﻦ‬
‫أرﺗﻴﺴﻮﻧﺎت‪/‬ﺑﻴﺮوﻧﺎرﻳﺪﻳﻦ‬
‫ﻛﻠﻮروﻛﻴﻦ]ﻣﻼﺣﻈﺔ ‪[29‬‬

‫دﻳﻬﻴﺪروارﺗﻴﻤﻴﺴﻴﻨﻴﻦ‪/‬ﺑﻴﺒﻴﺮاﻛﻴﻦ‬
‫دوﻛﺴﻴﺴﺎﻳﻜﻠﻴﻦ]ﻣﻼﺣﻈﺔ ‪[30‬‬

‫ﻣﻔﻠﻮﻛﻮﻳﻦ]ﻣﻼﺣﻈﺔ ‪[24‬‬

‫ﺑﺮﻳﻤﺎﻛﻴﻦ]ﻣﻼﺣﻈﺔ ‪[31‬‬

‫ﻛﻴﻨﻴﻦ]ﻣﻼﺣﻈﺔ ‪[32‬‬
‫ﺳﻠﻔﺎدوﻛﺴﻴﻦ‪/‬ﺑﻴﺮﻳﻤﻴﺜﺎﻣﻴﻦ]ﻣﻼﺣﻈﺔ ‪[33‬‬

‫ﻟﻠﻮﻗﺎﻳﺔ‬

‫ﻛﻠﻮروﻛﻴﻦ]ﻣﻼﺣﻈﺔ ‪[34‬‬

‫دوﻛﺴﻴﺴﺎﻳﻜﻠﻴﻦ‬
‫ﻣﻔﻠﻮﻛﻮﻳﻦ‬
‫ﺑﺮوﻏﻮاﻧﻴﻞ]ﻣﻼﺣﻈﺔ ‪[35‬‬

‫ﻣﻀﺎدات داء اﻟﻤﺘﻜﻴﺴﺎت اﻟﺮﺋﻮﻳﺔ‬

‫وﻣﻀﺎدات داء اﻟﻤﻘﻮﺳﺎت‬

‫ﺑﻴﺮﻳﻤﻴﺜﺎﻣﻴﻦ‬
‫ﺳﻮﻟﻔﺎدﻳﺎزﻳﻦ‬
‫ﺗﺮﻳﻤﻴﺜﻮﺑﺮﻳﻢ‪/‬ﺳﻠﻔﺎﻣﻴﺜﻮﻛﺴﺎزول‬
‫ﺑﻴﻨﺘﺎﻣﻴﺪﻳﻦ‪α‬‬

‫ﻣﻀﺎدات اﻟﻤﺜﻘﺒﻴﺎت‬

‫داء اﻟﻤﺜﻘﺒﻴﺎت اﻷﻓﺮﻳﻘﻴﺔ‬

 ‫اﻟﻤﺮﺣﻠﺔ اﻷوﻟﻰ‬

‫ﺑﻴﻨﺘﺎﻣﻴﺪﻳﻦ]ﻣﻼﺣﻈﺔ ‪[36‬‬

‫ﺳﻮراﻣﻴﻦ]ﻣﻼﺣﻈﺔ ‪[37‬‬

‫اﻟﻤﺮﺣﻠﺔ اﻟﺜﺎﻧﻴﺔ‬

‫إﻓﻠﻮرﻧﻴﺘﻴﻦ]ﻣﻼﺣﻈﺔ ‪[38‬‬

‫ﻣﻴﻼرﺳﻮﺑﺮول‬
‫ﻧﻴﻔﻮرﺗﻴﻤﻮﻛﺲ]ﻣﻼﺣﻈﺔ ‪[39‬‬

‫داء اﻟﻤﺜﻘﺒﻴﺎت اﻷﻣﺮﻳﻜﻴﺔ‬

‫ﺑﻨﺰﻧﻴﺪازول‬
‫ﻧﻴﻔﻮرﺗﻴﻤﻮﻛﺲ‬

‫ﻣﻀﺎدات اﻟﺼﺪاع اﻟﻨﺼﻔﻲ‬

‫اﻟﻨﻮﺑﺎت اﻟﺤﺎدة‬
 ‫ﺣﻤﺾ أﺳﻴﺘﻴﻞ ﺳﺎﻟﻴﺴﻴﻠﻴﻚ )أﺳﺒﺮﻳﻦ(‬
‫إﻳﺒﻮﺑﺮوﻓﻴﻦ‬
‫ﺑﺎراﺳﻴﺘﺎﻣﻮل‬

‫اﻟﻮﻗﺎﻳﺔ‬

‫ﺑﺮوﺑﺮاﻧﻮﻟﻮل‬

‫ﻣﻀﺎدات اﻷورم وﻛﺎﺑﺘﺎت اﻟﻤﻨﺎﻋﺔ‬

‫ﻛﺎﺑﺘﺎت اﻟﻤﻨﺎﻋﺔ‬
‫آزاﺛﻴﻮﺑﺮﻳﻦ‪α‬‬

‫ﺳﻴﻜﻠﻮﺳﺒﻮرﻳﻦ‪α‬‬

‫اﻷدوﻳﺔ اﻟﺴﺎﻣﺔ ﻟﻠﺨﻼﻳﺎ وﻣﺴﺎﻋﺪﺗﻬﺎ‬

‫)ﺗﺮﻳﺘﻴﻨﻮﻳﻦ(‪α‬‬ ‫ﺣﻤﺾ اﻟﺮﻳﺘﻴﻨﻮﻳﻚ اﻟﻤﻔﺮوق‬
‫أﻟﻮﺑﻴﻮرﻳﻨﻮل‪α‬‬

‫أﺳﺒﺎراﺟﻴﻨﺎز‪α‬‬
 ‫ﺑﻴﻨﺪاﻣﻮﺳﺘﻴﻦ‪α‬‬

‫ﺑﻠﻴﻮﻣﻴﺴﻴﻦ‪α‬‬

‫اﻟﻔﻮﻟﻴﻨﻴﻚ‪α‬‬ ‫ﺣﻤﺾ‬
‫ﻛﺎﺑﺴﻴﺘﺎﺑﻴﻦ‪α‬‬

‫ﻛﺮﺑﻮﺑﻼﺗﻴﻦ‪α‬‬

‫ﻛﻠﻮراﻣﺒﻮﺳﻴﻞ‪α‬‬

‫ﺳﻴﺴﺒﻼﺗﻴﻦ‪α‬‬

‫ﺳﻴﻜﻠﻮﻓﻮﺳﻔﺎﻣﻴﺪ‪α‬‬

‫ﺳﻴﺘﺎراﺑﻴﻦ‪α‬‬

‫داﻛﺎرﺑﺎزﻳﻦ‪α‬‬

‫داﻛﺘﻴﻨﻮﻣﻴﺴﻴﻦ‪α‬‬

‫داﺳﺎﺗﻴﻨﻴﺐ‪α‬‬

‫داوﻧﻮروﺑﻴﺴﻴﻦ‪α‬‬

‫دوﺳﻴﺘﺎﻛﺴﻴﻞ‪α‬‬
 ‫دوﻛﺴﻮروﺑﻴﺴﻴﻦ‪α‬‬

‫إﻳﺘﻮﺑﻮزﻳﺪ‪α‬‬

‫ﻓﻴﻠﻐﺮاﺳﺘﻴﻢ‪α‬‬

‫ﻓﻠﻮداراﺑﻴﻦ‪α‬‬

‫ﻓﻠﻮروﻳﻮراﺳﻴﻞ‪α‬‬

‫ﺟﻴﻤﺴﻴﺘﺎﺑﻴﻦ‪α‬‬

‫ﻳﻮرﻳﺎ‪α‬‬ ‫ﻫﻴﺪروﻛﺴﻲ‬
‫إﻳﻔﺴﻔﺎﻣﻴﺪ‪α‬‬

‫إﻳﻤﺎﺗﻴﻨﺐ‪α‬‬

‫إرﻳﻨﻮﺗﻴﻜﺎن‪α‬‬

‫ﻣﺮﻛﺎﺑﺘﻮﺑﻮرﻳﻦ‪α‬‬

‫ﻣﻴﺴﻨﺎ‪α‬‬

‫ﻣﻴﺜﻮﺗﺮﻛﺴﻴﺖ‪α‬‬

‫أوﻛﺴﺎﻟﻴﺒﻼﺗﻴﻦ‪α‬‬
 ‫ﺑﺎﻛﻠﻴﺘﺎﻛﺴﻴﻞ‪α‬‬

‫ﺑﺮوﻛﺎرﺑﺎزﻳﻦ‪α‬‬

‫رﻳﺘﻮﻛﺴﻴﻤﺎب‪α‬‬

‫ﺛﻴﻮﻏﻮاﻧﻴﻦ‪α‬‬

‫ﺗﺮازﺗﻮزوﻣﺎب‪α‬‬

‫ﻓﻴﻨﺒﻼﺳﺘﻴﻦ‪α‬‬

‫ﻓﻴﻨﻜﺮﻳﺴﺘﻴﻦ‪α‬‬

‫ﻓﻴﻨﻮرﻟﺒﻴﻦ‪α‬‬

‫زوﻟﻴﺪروﻧﻴﻚ‪α‬‬ ‫ﺣﻤﺾ‬

‫اﻟﻬﺮﻣﻮﻧﺎت وﻣﻀﺎداﺗﻬﺎ‬
‫أﻧﺎﺳﺘﺮوزول‪α‬‬

‫ﺑﻴﻜﺎﻟﻮﺗﺎﻣﻴﺪ‪α‬‬

‫دﻳﻜﺴﺎﻣﻴﺘﺎزون‪α‬‬

‫ﻫﻴﺪروﻛﻮرﺗﻴﺰون‪α‬‬
 ‫ﻟﻮﺑﺮوﻟﻴﻦ‪α‬‬

‫ﻣﻴﺜﻴﻠﺒﺮﻳﺪﻧﻴﺰوﻟﻮن‪α‬‬

‫ﺑﺮﻳﺪﻧﻴﺰوﻟﻮن‪α‬‬

‫ﺗﺎﻣﻮﻛﺴﻴﻔﻴﻦ‪α‬‬

‫ﻣﻀﺎدات ﺑﺎرﻛﻨﺴﻮﻧﻴﺔ‬
‫ﺑﻴﺒﻴﺮﻳﺪﻳﻦ‬
‫ﻛﺮﺑﻴﺪوﺑﺎ‪/‬ﻟﻴﻔﻮدوﺑﺎ )ﻟﻴﻔﻮدوﺑﺎ ‪ +‬ﻛﺮﺑﻴﺪوﺑﺎ(‬

‫أدوﻳﺔ ﺗﺆﺛﺮ ﻋﻠﻰ اﻟﺪم‬

‫ﻣﻀﺎدات ﻓﻘﺮ اﻟﺪم‬

‫ﻣﻠﺢ اﻟﺤﺪﻳﺪوز‬
‫ﻣﻠﺢ اﻟﺤﺪﻳﺪوز‪/‬ﺣﻤﺾ اﻟﻔﻮﻟﻴﻚ‬
‫ﺣﻤﺾ اﻟﻔﻮﻟﻴﻚ‬
‫ﻫﻴﺪروﻛﺴﻮﺑﺎﻻﻣﻴﻦ‬
 ‫اﻟﺤﻤﺮ‪α‬‬ ‫ﻋﺎﻣﻞ ﻣﻨﺒﻪ ﻟﺘﻜﻮﻳﻦ اﻟﻜﺮﻳﺎت‬

‫أدوﻳﺔ ﺗﺆﺛﺮ ﻋﻠﻰ اﻟﺘﺨﺜﺮ‬

‫إﻳﻨﻮﻛﺴﺎﺑﺎرﻳﻦ‬
‫ﻫﻴﺒﺎرﻳﻦ‬
‫ﻓﻴﺘﻮﻣﻴﻨﺎدﻳﻮن‬
‫ﻛﺒﺮﻳﺘﺎت اﻟﺒﺮوﺗﺎﻣﻴﻦ‬
‫ﺣﻤﺾ اﻟﺘﺮاﻧﻴﻜﺴﺎﻣﻴﻚ‬
‫وارﻓﺎرﻳﻦ‬
‫دزﻣﻮﺑﺮﻳﺴﻴﻦ‪α‬‬

‫أدوﻳﺔ أﺧﺮى ﻟﻼﻋﺘﻼﻻت‬

‫اﻟﻬﻴﻤﻮﻏﻠﻮﺑﻴﻨﻴﺔ‬
‫دﻳﻔﻴﺮوﻛﺴﺎﻣﻴﻦ‪]α‬ﻣﻼﺣﻈﺔ ‪[40‬‬

‫ﻳﻮرﻳﺎ‪α‬‬ ‫ﻫﻴﺪروﻛﺴﻲ‬

‫ﻣﻨﺘﺠﺎت اﻟﺪم وﺑﺪاﺋﻞ اﻟﺒﻼزﻣﺎ ذات‬

 ‫اﻷﺻﻞ اﻟﺒﺸﺮي‬
‫اﻟﺪم وﻣﻜﻮﻧﺎﺗﻪ‬

‫ﻛَﻴﺲ ﻳﺤﺘﻮي ﻋﻠﻰ وﺣﺪة ﻣﻦ اﻟﺒﻼزﻣﺎ اﻟﻤﺘﺠﻤﺪة اﻟﺠﺪﻳﺪة‬

‫ﺑﻼزﻣﺎ ﻣﺘﺠﻤﺪة ﺟﺪﻳﺪة‬

‫ﻧﻘﻞ اﻟﺼﻔﺎﺋﺢ اﻟﺪﻣﻮﻳﺔ‬
‫ﻛﺮﻳﺎت اﻟﺪم اﻟﺤﻤﺮاء اﻟﻤﻜﺪﺳﺔ‬
‫دم ﻛﺎﻣﻞ‬

‫أدوﻳﺔ ﻣﺸﺘﻘﺔ ﻣﻦ اﻟﺒﻼزﻣﺎ‬

 ‫ﻏﻠﻮﺑﻮﻟﻴﻨﺎت ﻣﻨﺎﻋﻴﺔ ﺑﺸﺮﻳﺔ‬

‫ﻏﻠﻮﺑﻮﻟﻴﻦ اﻟﺮﻳﺴﻮس اﻟﻤﻨﺎﻋﻲ‬

‫ﻏﻠﻮﺑﻮﻟﻴﻦ ﻣﻨﺎﻋﻲ ﻣﻀﺎد ﻟﻠﻜﻠﺐ‬
‫ﻏﻠﻮﺑﻴﻮﻟﻴﻦ ﻣﻨﺎﻋﻲ ﻣﻀﺎد ﻟﻠﻜﺰاز‬
‫اﻟﻤﻨﺎﻋﻲ‪α‬‬ ‫ﻣﻌﺎﻟﺠﺔ ﺑﺎﻟﻐﻠﻮﺑﻴﻮﻟﻴﻦ‬

‫ﻋﻮاﻣﻞ ﺗﺨﺜﺮ اﻟﺪم‬

‫اﻟﺜﺎﻣﻦ‪α‬‬ ‫ﻋﺎﻣﻞ اﻟﺘﺠﻠﻂ‬

‫اﻟﺘﺎﺳﻊ‪α‬‬ ‫ﻋﺎﻣﻞ اﻟﺘﺠﻠﻂ‬

‫ﺑﺪاﺋﻞ اﻟﺒﻼزﻣﺎ‬
‫‪]70‬ﻣﻼﺣﻈﺔ ‪[41‬‬ ‫دﻳﻜﺴﺘﺮان‬

‫أدوﻳﺔ ﻗﻠﺒﻴﺔ وﻋﺎﺋﻴﺔ‬

‫ﻣﻀﺎدات اﻟﺬﺑﺤﺔ‬
 ‫ﺑﻴﺴﻮﺑﺮوﻟﻮل]ﻣﻼﺣﻈﺔ ‪[42‬‬

‫ﺛﻼﺛﻲ ﻧﺘﺮات اﻟﻐﻠﻴﺴﻴﺮﻳﻞ‬

‫آﻳﺰوﺳﻮرﺑﺎﻳﺪ ﺛﻨﺎﺋﻲ اﻟﻨﺘﺮات‬
‫ﻓﻴﺮاﺑﺎﻣﻴﻞ‬

‫ﻣﻀﺎدات اﺿﻄﺮاب اﻟﻨﻈﻢ‬

‫ﺑﻴﺴﻮﺑﺮوﻟﻮل]ﻣﻼﺣﻈﺔ ‪[42‬‬

‫دﻳﺠﻮﻛﺴﻴﻦ‬
‫إﺑﻴﻨﻴﻔﺮﻳﻦ )أدرﻳﻨﺎﻟﻴﻦ(‬
‫ﻟﻴﺪوﻛﺎﺋﻴﻦ‬
‫ﻓﻴﺮاﺑﺎﻣﻴﻞ‬
‫أﻣﻴﻮدارون‪α‬‬

‫ﻣﻀﺎدات ﻓﺮط ﺿﻐﻂ اﻟﺪم‬

‫أﻣﻠﻮدﻳﺒﻴﻦ‬
‫ﺑﻴﺴﻮﺑﺮوﻟﻮل]ﻣﻼﺣﻈﺔ ‪[42‬‬
 ‫إﻧﺎﻻﺑﺮﻳﻞ‬
‫ﻫﻴﺪراﻻزﻳﻦ]ﻣﻼﺣﻈﺔ ‪[43‬‬

‫ﻫﻴﺪروﻛﻠﻮرﺛﻴﺎزﻳﺪ‬
‫ﻣﺜﻴﻠﺪوﺑﺎ]ﻣﻼﺣﻈﺔ ‪[44‬‬

‫ﻟﻮﺳﺎرﺗﺎن‬
‫اﻟﺼﻮدﻳﻮم‪α‬‬ ‫ﻧﺘﺮوﺑﺮوﺳﻴﺪ‬

‫أدوﻳﺔ ُﺗﺴﺘﺨﺪم ﻓﻲ ﻓﺸﻞ اﻟﻘﻠﺐ‬

‫ﺑﻴﺴﻮﺑﺮوﻟﻮل]ﻣﻼﺣﻈﺔ ‪[42‬‬

‫دﻳﺠﻮﻛﺴﻴﻦ‬
‫إﻧﺎﻻﺑﺮﻳﻞ‬
‫ﻓﻮروﺳﻴﻤﻴﺪ‬
‫ﻫﻴﺪروﻛﻠﻮرﺛﻴﺎزﻳﺪ‬
‫ﻟﻮﺳﺎرﺗﺎن‬
‫ﺳﺒﻴﺮوﻧﻮﻻﻛﺘﻮن‬
 ‫)دواء(‪α‬‬ ‫دوﺑﺎﻣﻴﻦ‬

‫ﻣﻀﺎدات اﻟﺨﺜﺎر‬

‫ﻣﻀﺎدات اﻟﺼﻔﻴﺤﺎت‬

‫ﺣﻤﺾ أﺳﻴﺘﻴﻞ ﺳﺎﻟﻴﺴﻴﻠﻴﻚ )أﺳﺒﺮﻳﻦ(‬

‫ﻛﻠﻮﺑﻴﺪوﻏﺮﻳﻞ‬

‫أدوﻳﺔ ﺣﺎﻟﺔ ﻟﻠﺨﺜﺮة‬

‫ﺳﺘﺮﺑﺘﻮﻛﻴﻨﺎز‪α‬‬

‫ﻋﻮاﻣﻞ ﺧﺎﻓﻀﺔ ﻟﻠﺸﺤﻮم‬

‫ﺳﻴﻤﻔﺎﺳﺘﺎﺗﻴﻦ]ﻣﻼﺣﻈﺔ ‪[45‬‬

‫أدوﻳﺔ ﺟﻠﺪﻳﺔ )ﻣﻮﺿﻌﻴﺔ(‬

‫ﻣﻀﺎدات اﻟﻔﻄﺮﻳﺎت‬

‫ﻣﻴﻜﻮﻧﺎزول‬
 ‫ﺛﻨﺎﺋﻲ ﻛﺒﺮﻳﺘﻴﺪ اﻟﺴﻴﻠﻴﻨﻴﻮم‬
‫ﺛﻴﻮﺳﻠﻔﺎت اﻟﺼﻮدﻳﻮم‬
‫ﺗﻴﺮﺑﻴﻨﺎﻓﻴﻦ‬

‫ﻣﻀﺎدات اﻟﻌﺪوى‬

‫ﻣﻮﺑﻴﺮوﺳﻴﻦ‬
‫ﺑﺮﻣﻨﻐﻨﺎت اﻟﺒﻮﺗﺎﺳﻴﻮم‬
‫ﺳﻠﻔﺎدﻳﺎزﻳﻦ اﻟﻔﻀﺔ‬

‫ﻣﻀﺎدات اﻻﻟﺘﻬﺎب وﻣﻀﺎدات اﻟﺤﻜﺔ‬

‫ﺑﻴﺘﺎﻣﻴﺜﺎزون‬
‫ﻛﺎﻻﻣﻴﻦ‬
‫ﻫﻴﺪروﻛﻮرﺗﻴﺰون‬

‫أدوﻳﺔ ﺗﺆﺛﺮ ﻋﻠﻰ ﺗﻜﺎﺛﺮ وﺗﻤﺎﻳﺰ اﻟﺠﻠﺪ‬

‫ﺑﻴﺮوﻛﺴﻴﺪ اﻟﺒﻨﺰوﻳﻞ‬
 ‫ﻗﻄﺮان اﻟﻔﺤﻢ‬
‫ﻓﻠﻮروﻳﻮراﺳﻴﻞ‬
‫راﺗﻨﺞ اﻟﺒﻮدوﻓﻴﻠﻮم‬
‫ﺣﻤﺾ اﻟﺴﺎﻟﻴﺴﻠﻴﻚ‬
‫ﻛﺮﻳﻢ ﻣﺤﺘﻮي ﻋﻠﻰ اﻟﻴﻮرﻳﺎ‬

‫ﻣﻀﺎدات اﻟﺠﺮب وﻣﻀﺎدات اﻟﻘﻤﻞ‬

‫ﺑﻨﺰوات اﻟﺒﻨﺰﻳﻞ‬
‫ﺑﻴﺮﻣﺜﺮﻳﻦ‬

‫ﻋﻮاﻣﻞ اﻟﺘﺸﺨﻴﺺ‬
‫أدوﻳﺔ اﻟﻌﻴﻮن‬

‫ﻓﻠﻮرﻳﺴﺌﻴﻦ‬
‫ﺗﺮوﺑﻴﻜﺎﻣﻴﺪ‬

‫ﻣﻮاد ﻇﻠﻴﻠﺔ )ﻋﺘﻴﻤﺔ ﻟﻸﺷﻌﺔ(‬

 ‫أﻣﻴﺪوﺗﺮﻳﺰوات‬
‫ﻛﺒﺮﻳﺘﺎت اﻟﺒﺎرﻳﻮم‬
‫ﻳﻮﻫﻜﺴﻮل‬
‫اﻟﻤﻴﻐﻠﻮﻣﻴﻦ‪α‬‬ ‫ﻳﻮﺗﺮوﻛﺴﻴﺖ‬

‫اﻟﻤﻄﻬﺮات واﻟﻤﻌﻘﻤﺎت‬
‫اﻟﻤﻌﻘﻤﺎت‬

‫ﻛﻠﻮرﻫﻴﻜﺴﻴﺪﻳﻦ‬
‫إﻳﺜﺎﻧﻮل‬
‫ﺑﻮﻓﻴﺪون ﻳﻮدي‬

‫اﻟﻤﻄﻬﺮات‬

‫ﻛﺤﻮل ﺗﺴﺘﻨﺪ ﻋﻠﻰ ﻓﺮك اﻟﻴﺪ‬

‫ﻣﺮﻛﺐ ﻗﺎﻋﺪة اﻟﻜﻠﻮر‬
‫ﻛﻠﻮروزاﻳﻠﻴﻨﻮل‬
 ‫ﻏﻠﻮﺗﺎرال‬

‫ﻣﺪرات اﻟﺒﻮل‬
‫أﻣﻴﻠﻮرﻳﺪ‬
‫ﻓﻮروﺳﻴﻤﻴﺪ‬
‫ﻫﻴﺪروﻛﻠﻮرﺛﻴﺎزﻳﺪ‬
‫ﻣﺎﻧﻴﺘﻮل‬
‫ﺳﺒﻴﺮوﻧﻮﻻﻛﺘﻮن‬

‫أدوﻳﺔ ﻫﻀﻤﻴﺔ‬
‫ﺑﻨﻜﺮﻳﺎﺳﻴﺔ‪α‬‬ ‫إﻧﺰﻳﻤﺎت‬

‫ﻣﻀﺎدات اﻟﺘﻘﺮح‬

‫أوﻣﻴﺒﺮازول‬
‫راﻧﻴﺘﻴﺪﻳﻦ‬

‫ﻣﻀﺎدات اﻟﻘﻲء‬
 ‫دﻳﻜﺴﺎﻣﻴﺘﺎزون‬
‫ﻣﻴﺘﻮﻛﻠﻮﺑﺮاﻣﻴﺪ‬
‫أوﻧﺪاﻧﺴﻴﺘﺮون‬

‫ﻣﻀﺎدات اﻻﻟﺘﻬﺎب‬

‫ﺳﻠﻔﺎﺳﺎﻻزﻳﻦ‬
‫ﻫﻴﺪروﻛﻮرﺗﻴﺰون‪α‬‬

‫ﻣﻠﻴﻨﺎت‬

‫ﻏﻠﻴﻜﻮزﻳﺪ ﺳﻨﺎﻣﻜﻲ‬

‫أدوﻳﺔ اﻹﺳﻬﺎل‬

‫إﻣﻬﺎء ﻓﻤﻮي‬

‫أﻣﻼح اﻹﻣﻬﺎء اﻟﻔﻤﻮي‬

‫أدوﻳﺔ اﻹﺳﻬﺎل ﻓﻲ اﻷﻃﻔﺎل‬

‫اﻟﺰﻧﻚ]ﻣﻼﺣﻈﺔ ‪[46‬‬ ‫ﻛﺒﺮﻳﺘﺎت‬

‫اﻟﻬﺮﻣﻮﻧﺎت واﻷدوﻳﺔ اﻟﺼﻤﺎوﻳﺔ اﻷﺧﺮى‬
‫وﻣﺎﻧﻌﺎت اﻟﺤﻤﻞ‬
‫ﻫﺮﻣﻮﻧﺎت اﻟﻐﺪة اﻟﻜﻈﺮﻳﺔ واﻟﺒﺪاﺋﻞ‬
‫اﻟﺼﻨﺎﻋﻴﺔ‬

‫ﻓﻠﻮدروﻛﻮرﺗﻴﺰون‬
‫ﻫﻴﺪروﻛﻮرﺗﻴﺰون‬

‫أﻧﺪروﺟﻴﻨﺎت‬
‫ﺗﺴﺘﻮﺳﺘﻴﺮون‪α‬‬

‫ﻣﺎﻧﻌﺎت اﻟﺤﻤﻞ‬

‫ﻣﺎﻧﻌﺎت اﻟﺤﻤﻞ ﺑﺎﻟﻬﺮﻣﻮﻧﺎت اﻟﻔﻤﻮﻳﺔ‬

‫إﻳﺜﻴﻨﻴﻞ إﺳﺘﺮادﻳﻮل‪/‬ﻟﻴﻔﻮﻧﻮﺟﻴﺴﺘﺮﻳﻞ‬
‫إﻳﺜﻴﻨﻴﻞ إﺳﺘﺮادﻳﻮل‪/‬ﻧﻮرﻳﺜﻴﺴﺘﻴﺮون‬
‫ﻟﻴﻔﻮﻧﻮرﻏﻴﺴﺘﺮﻳﻞ‬
 ‫وﻟﻴﺒﺮﻳﺴﺘﺎل‬

‫ﻣﺎﻧﻌﺎت اﻟﺤﻤﻞ ﺑﺎﻟﻬﺮﻣﻮﻧﺎت اﻟﻘﺎﺑﻠﺔ ﻟﻠﺤﻘﻦ‬

‫ﺳﻴﺒﻴﻮﻧﺎت اﻹﺳﺘﺮادﻳﻮل‪/‬أﺳﻴﺘﺎت اﻟﻤﻴﺪروﻛﺴﻲ‬

‫ﺑﺮوﺟﺴﺘﻴﺮون‬
‫أﺳﻴﺘﺎت اﻟﻤﻴﺪروﻛﺴﻲ ﺑﺮوﺟﺴﺘﻴﺮون‬
‫إﻳﻨﺎﻧﺜﺎت اﻟﻨﻮرﻳﺜﻨﺪرون‬

‫ﻟﻮاﻟﺐ رﺣﻤﻴﺔ‬

‫ﻟﻮاﻟﺐ ﻧﺤﺎﺳﻴﺔ‬
‫ﻟﻮاﻟﺐ ﺑﺮوﺟﺴﺘﻮﺟﻴﻨﺔ‬

‫وﺳﺎﺋﻞ اﻟﻌﺰل‬

‫ﻋﻮازل ذﻛﺮﻳﺔ‬
‫ﻋﻮازل أﻧﺜﻮﻳﺔ‬

‫ﻣﺎﻧﻌﺎت اﻟﺤﻤﻞ اﻟﻘﺎﺑﻠﺔ ﻟﻠﻐﺮس‬

 ‫ﻏﺮﺳﺔ ﻣﻄﻠﻘﺔ ﻟﻺﺗﻮﻧﻮﺟﻴﺴﺘﺮﻳﻞ‬
‫ﻏﺮﺳﺔ ﻣﻄﻠﻘﺔ ﻟﻠﻴﻔﻮﻧﻮﺟﻴﺴﺘﺮﻳﻞ‬

‫ﻣﺎﻧﻌﺎت اﻟﺤﻤﻞ داﺧﻞ اﻟﻤﻬﺒﻞ‬

‫ﺣﻠﻘﺔ اﻟﻤﻬﺒﻞ اﻟﺒﺮوﺟﺴﺘﻴﺮوﻧﻴﺔ‬

‫اﻹﻧﺴﻮﻟﻴﻦ واﻷدوﻳﺔ اﻷﺧﺮى اﻟﻤُ ﺴﺘﻌﻤﻠﺔ‬

‫ﻓﻲ اﻟﺴﻜﺮي‬
‫ﻏﻠﻴﻜﻼزﻳﺪ]ﻣﻼﺣﻈﺔ ‪[47‬‬

‫ﻏﻠﻮﻛﺎﻏﻮن‬
‫ﺣﻘﻨﺔ اﻹﻧﺴﻮﻟﻴﻦ‬
‫أﻧﺴﻮﻟﻴﻦ ﻣﺘﻮﺳﻂ اﻟﻤﻔﻌﻮل‬
‫ﻣﻴﺘﻔﻮرﻣﻴﻦ‬

‫ﻣﺤﻔﺰات اﻟﺘﺒﻮﻳﺾ‬
‫ﻛﻠﻮﻣﻴﻔﻴﻦ‪α‬‬

‫ﺑﺮوﺟﺴﺘﻮﺟﻴﻨﺎت‬
 ‫أﺳﻴﺘﺎت اﻟﻤﻴﺪروﻛﺴﻲ ﺑﺮوﺟﺴﺘﻴﺮون‬

‫ﻫﺮﻣﻮﻧﺎت اﻟﻐﺪة اﻟﺪرﻗﻴﺔ واﻷدوﻳﺔ‬

‫اﻟﻤﻀﺎدة ﻟﻨﺸﺎط اﻟﺪرﻗﻴﺔ‬

‫ﻟﻴﻔﻮﺛﻴﺮوﻛﺴﻴﻦ‬
‫ﻳﻮدﻳﺪ اﻟﺒﻮﺗﺎﺳﻴﻮم‬
‫ﺑﺮوﺑﻴﻞ ﺛﻴﻮراﺳﻴﻞ‬
‫ﻟﻮﻏﻮل‪α‬‬ ‫ﻣﺤﻠﻮل‬

‫أدوﻳﺔ ﻣﻨﺎﻋﻴﺔ‬
‫ﻋﻮاﻣﻞ اﻟﺘﺸﺨﻴﺺ‬

‫ﺗﻮﺑﺮﻛﻮﻟﻴﻦ‪ ،‬ﻣﺸﺘﻖ ﺑﺮوﺗﻴﻨﻲ ﻣﻨﻘﻰ‬

‫اﻷﻣﺼﺎل واﻟﻐﻠﻮﺑﻮﻟﻴﻨﺎت اﻟﻤﻨﺎﻋﻴﺔ‬

‫ﻟﻠﺴﻤﻢ]ﻣﻼﺣﻈﺔ ‪[48‬‬ ‫ﻏﻠﻮﺑﻮﻟﻴﻦ ﻣﻨﺎﻋﻲ ﻣﻀﺎد‬
‫ﺿﺪ ذﻳﻔﺎن اﻟﺨﻨﺎق‬
 ‫اﻟﻠﻘﺎﺣﺎت‬

‫زﺟﺎﺟﺔ ُﻟﻘﺎح اﻟﻜﻮﻟﻴﺮا ﻋﺒﺮ َ‬

‫اﻟﻔﻢ‬

‫ﻟﻘﺎح ﺑﻲ ﺳﻲ ﺟﻲ )ﻟﻘﺎح ﻋﺼﻴﺔ ﻛﺎﻟﻤﻴﺖ ﻏﻮﻳﺮن(‬

‫اﻟﻜﻮﻟﻴﺮا]ﻣﻼﺣﻈﺔ ‪[49‬‬ ‫ﻟﻘﺎح‬
‫ﻟﻘﺎح اﻟﺨﻨﺎق‬
‫ﻟﻘﺎح اﻟﻤﺴﺘﺪﻣﻴﺔ اﻟﻨﺰﻟﻴﺔ اﻟﻨﻮع ب‬
‫أ]ﻣﻼﺣﻈﺔ ‪[49‬‬ ‫ﻟﻘﺎح اﻟﺘﻬﺎب اﻟﻜﺒﺪ‬
‫ﻟﻘﺎح اﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﻔﻴﺮوﺳﻲ ب‬
‫ﻟﻘﺎح ﻓﻴﺮوس اﻟﻮرم اﻟﺤﻠﻴﻤﻲ اﻟﺒﺸﺮي‬
‫ﻟﻘﺎح اﻹﻧﻔﻠﻮﻧﺰا‬
 ‫اﻟﻴﺎﺑﺎﻧﻲ]ﻣﻼﺣﻈﺔ ‪[50‬‬ ‫ﻟﻘﺎح اﻟﺘﻬﺎب اﻟﺪﻣﺎغ‬
‫ﻟﻘﺎح اﻟﺤﺼﺒﺔ‬
‫ﻟﻘﺎح اﻟﺘﻬﺎب اﻟﺴﺤﺎﻳﺎ ﺑﺎﻟﻤﻜﻮرات‬
‫اﻟﺴﺤﺎﺋﻴﺔ]ﻣﻼﺣﻈﺔ ‪[49‬‬

‫ﻟﻘﺎح اﻟﻨﻜﺎف‬
‫ﻟﻘﺎح اﻟﺴﻌﺎل اﻟﺪﻳﻜﻲ‬
‫ﻟﻘﺎح اﻟﻤﻜﻮرة اﻟﺮﺋﻮﻳﺔ‬
‫ﻟﻘﺎح ﺷﻠﻞ اﻷﻃﻔﺎل‬
‫اﻟﻜﻠﺐ]ﻣﻼﺣﻈﺔ ‪[49‬‬ ‫ﻟﻘﺎح داء‬
‫ﻟﻘﺎح اﻟﻔﻴﺮوس اﻟﻌﺠﻠﻲ‬
‫ﻟﻘﺎح اﻟﺤﺼﺒﺔ اﻷﻟﻤﺎﻧﻴﺔ‬
‫ﻟﻘﺎح اﻟﻜﺰاز‬
‫ﺑﺎﻟﻘﺮاد]ﻣﻼﺣﻈﺔ ‪[50‬‬ ‫ﻟﻘﺎح اﻟﺘﻬﺎب اﻟﺪﻣﺎغ اﻟﻤﺤﻤﻮل‬
‫اﻟﺘﻴﻔﻮﺋﻴﺪ]ﻣﻼﺣﻈﺔ ‪[49‬‬ ‫ﻟﻘﺎح‬
‫ﻟﻘﺎح ﺟﺪري اﻟﻤﺎء‬
 ‫اﻟﺼﻔﺮاء]ﻣﻼﺣﻈﺔ ‪[50‬‬ ‫ﻟﻘﺎح اﻟﺤﻤﻰ‬

‫ﺑﺸﻜﻞ‬
‫ٍ‬ ‫ﻣﺮﺧﻴﺎت اﻟﻌﻀﻼت )ﺗﻌﻤﻞ‬
‫ﺧﺎرﺟﻲ( وﻣﺜﺒﻄﺎت اﻟﻜﻮﻟﻴﻨﺴﺘﻴﺮاز‬
‫أﺗﺮاﻛﻮرﻳﻮم‬
‫ﻧﻴﻮﺳﺘﻐﻤﻴﻦ‬
‫ﺳﻜﺴﻨﻴﻞ ﻛﻮﻟﻴﻦ‬
‫ﻓﻴﻜﻮروﻧﻴﻮم‬
‫ﺑﻴﺮﻳﺪوﺳﺘﻴﻐﻤﻴﻦ‪α‬‬

‫ﻣﺴﺘﺤﻀﺮات اﻟﻌﻴﻮن‬
‫ﻣﻀﺎدات اﻟﻌﺪوى‬

‫آﺳﻴﻜﻠﻮﻓﻴﺮ‬
‫أزﻳﺜﺮوﻣﺎﻳﺴﻴﻦ‬
‫إرﻳﺜﺮوﻣﻴﺴﻴﻦ‬
 ‫ﺟﻨﺘﺎﻣﻴﺴﻴﻦ‬
‫ﻧﺎﺗﺎﻣﻴﺴﻴﻦ‬
‫أوﻓﻠﻮﻛﺴﺎﺳﻴﻦ‬
‫ﺗﻴﺘﺮاﺳﺎﻳﻜﻠﻦ‬

‫ﻣﻀﺎدات اﻻﻟﺘﻬﺎب‬

‫ﺑﺮﻳﺪﻧﻴﺰوﻟﻮن‬

‫ﻣُ ﺨﺪرات ﻣﻮﺿﻌﻴﺔ‬

‫ﺗﻴﺘﺮاﻛﺎﺋﻴﻦ‬

‫ﻣﻀﻴﻘﺎت اﻟﺤﺪﻗﺔ وﻣﻀﺎدات اﻟﺰرق‬

‫أﺳﻴﺘﺎزوﻻﻣﻴﺪ‬
‫ﻻﺗﺎﻧﻮﺑﺮوﺳﺖ‬
‫ﺑﻴﻠﻮﻛﺎرﺑﻴﻦ‬
‫ﺗﻴﻤﻮﻟﻮل‬
 ‫ﻣﻮﺳﻌﺎت اﻟﺤﺪﻗﺔ‬
‫أﺗﺮوﺑﻴﻦ]ﻣﻼﺣﻈﺔ ‪[51‬‬

‫)أدرﻳﻨﺎﻟﻴﻦ(‪α‬‬ ‫إﺑﻴﻨﻴﻔﺮﻳﻦ‬

‫ﻣﻀﺎدات ﻋﺎﻣﻞ اﻟﻨﻤﻮ اﻟﺒﻄﺎﻧﻲ اﻟﻮﻋﺎﺋﻲ‬

‫ﺑﻴﻔﺎﺳﻴﺰوﻣﺎب‪α‬‬

‫ﻣﻌﺠﻼت اﻟﻮﻻدة وﻣﻀﺎداﺗﻬﺎ‬

‫ﻣﻌﺠﻼت اﻟﻮﻻدة واﻟﻤﺠﻬﻀﺎت‬

‫إرﻏﻮﻣﺘﺮﻳﻦ‬
‫ﻣﻴﺰوﺑﺮوﺳﺘﻮل‬
‫أوﻛﺴﻴﺘﻮﺳﻴﻦ‬
‫ﻣﻴﻔﻴﺒﺮﻳﺴﺘﻮن ﻳُ ﺴﺘﺨﺪم ﻣﻊ‬
‫اﻟﻤﻴﺰوﺑﺮوﺳﺘﻮل‪]α‬ﻣﻼﺣﻈﺔ ‪[52‬‬

‫ﻣﻀﺎدات ﻣﻌﺠﻼت اﻟﻮﻻدة )ﺣﺎﻻت‬

 ‫اﻟﻤﺨﺎض(‬

‫ﻧﻴﻔﻴﺪﻳﺒﻴﻦ‬

‫ﻣﺤﺎﻟﻴﻞ اﻟﺪﻳﻠﺰة اﻟﺒﺮﻳﺘﻮﻧﻴﺔ‬

‫ﻣﻨﺎﺳﺐ(‪α‬‬
‫)ﺑﺘﻜﻮﻳﻦ ُ‬
‫ٍ‬ ‫ﻣﺤﻠﻮل اﻟﺪﻳﻠﺰة داﺧﻞ اﻟﺒﺮﻳﺘﻮن‬

‫أدوﻳﺔ اﻻﺿﻄﺮاﺑﺎت اﻟﻨﻔﺴﻴﺔ واﻟﺴﻠﻮﻛﻴﺔ‬

‫أدوﻳﺔ ﺗﺴﺘﺨﺪم ﻓﻲ اﻻﺿﻄﺮاﺑﺎت‬
‫اﻟﺬﻫﺎﻧﻴﺔ‬

‫ﻛﻠﻮرﺑﺮوﻣﺎزﻳﻦ‬
‫ﻓﻠﻮﻓﻴﻨﺎزﻳﻦ‬
‫ﻫﺎﻟﻮﺑﻴﺮﻳﺪول‬
‫رﻳﺴﺒﻴﺮﻳﺪون‬
‫ﻛﻠﻮزاﺑﻴﻦ‪α‬‬

‫أدوﻳﺔ ﺗﺴﺘﺨﺪم ﻓﻲ اﺿﻄﺮاﺑﺎت اﻟﻤﺰاج‬

 ‫أدوﻳﺔ ﺗﺴﺘﺨﺪم ﻓﻲ اﻻﺿﻄﺮاﺑﺎت‬
‫اﻻﻛﺘﺌﺎﺑﻴﺔ‬

‫أﻣﻴﺘﺮﺑﺘﻴﻠﻴﻦ‬
‫ﻓﻠﻮﻛﺴﻴﺘﻴﻦ‬
‫أدوﻳﺔ ﺗﺴﺘﺨﺪم ﻓﻲ اﻻﺿﻄﺮب ذو‬
‫اﻻﺗﺠﺎﻫﻴﻦ‬

‫ﻛﺎرﺑﺎﻣﺎزﻳﺒﻴﻦ‬
‫ﻟﻴﺜﻴﻮم‬
‫ﺣﻤﺾ اﻟﻔﺎﻟﺒﺮوﻳﻚ )ﻓﺎﻟﺒﺮوات اﻟﺼﻮدﻳﻮم(‬

‫أدوﻳﺔ ﺗﺴﺘﺨﺪم ﻓﻲ اﺿﻄﺮاﺑﺎت اﻟﻘﻠﻖ‬

‫دﻳﺎزﻳﺒﺎم‬

‫أدوﻳﺔ ﺗﺴﺘﺨﺪم ﻓﻲ اﻻﺿﻄﺮاﺑﺎت‬

‫اﻟﻮﺳﻮاﺳﻴﺔ اﻟﻘﻬﺮﻳﺔ‬

‫ﻛﻠﻮﻣﻴﺒﺮاﻣﻴﻦ‬
 ‫أدوﻳﺔ ﺗﺴﺘﺨﺪم ﻓﻲ اﻻﺿﻄﺮاﺑﺎت‬
‫اﻟﻨﺎﺟﻤﺔ ﻋﻦ اﺳﺘﻌﻤﺎل اﻟﻤﻮاد ﻧﻔﺴﻴﺔ‬
‫اﻟﻤﻔﻌﻮل‬

‫ﻣﻌﺎﻟﺠﺔ اﻟﻨﻴﻜﻮﺗﻴﻦ ﺑﺎﻹﻋﺎﺿﺔ‬

‫ﻣﻴﺜﺎدون‪α‬‬

‫أدوﻳﺔ ﺗﻌﻤﻞ ﻋﻠﻰ اﻟﺠﻬﺎز اﻟﺘﻨﻔﺴﻲ‬

‫ﻣﻀﺎد اﻟﺮﺑﻮ وأدوﻳﺔ داء اﻻﻧﺴﺪاد‬
‫اﻟﺮﺋﻮي اﻟﻤﺰﻣﻦ‬

‫ﺑﻴﻜﻠﻮﻣﻴﺘﺎزون‬
‫ﺑﻴﻮدﻳﺴﻮﻧﻴﺪ‬
‫ﺑﻮدﻳﺴﻮﻧﻴﺪ‪/‬ﻓﻮرﻣﻮﺗﻴﺮول‬
‫إﺑﻴﻨﻴﻔﺮﻳﻦ )أدرﻳﻨﺎﻟﻴﻦ(‬
‫إﺑﺮاﺗﺮوﺑﻴﻮم ﺑﺮوﻣﻴﺪ‬
‫ﺳﺎﻟﺒﻮﺗﺎﻣﻮل )أﻟﺒﻮﺗﻴﺮول(‬
‫ﻣﺤﺎﻟﻴﻞ ُﺗﺼﺤﺢ اﺿﻄﺮاﺑﺎت اﻟﻤﺎء‬
‫واﻟﻜﻬﺮل واﻟﺤﻤﺾ‪-‬ﻗﺎﻋﺪة‬
‫ً‬
‫ﻓﻤﻮﻳﺎ‬

‫أﻣﻼح اﻹﻣﻬﺎء اﻟﻔﻤﻮي‬

‫ﻛﻠﻮرﻳﺪ اﻟﺒﻮﺗﺎﺳﻴﻮم‬

‫ﺣﻘ ًﻨﺎ‬

‫ﻏﻠﻮﻛﻮز‬
‫ﻏﻠﻮﻛﻮز ﻣﻊ ﻛﻠﻮرﻳﺪ اﻟﺼﻮدﻳﻮم‬
‫ﻛﻠﻮرﻳﺪ اﻟﺒﻮﺗﺎﺳﻴﻮم‬
‫ﻛﻠﻮرﻳﺪ اﻟﺼﻮدﻳﻮم‬
‫ﻛﺮﺑﻮﻧﺎت اﻟﺼﻮدﻳﻮم اﻟﻬﻴﺪروﺟﻴﻨﻴﺔ‬
‫ﻣﺤﻠﻮل رﻳﻨﻐﺮ اﻟﻼﻛﺘﺎﺗﻲ‬

‫ﻣُ ﺘﻔﺮﻗﺎت‬
 ‫ﻣﺎء ﻟﻠﺤﻘﻦ‬

‫اﻟﻔﻴﺘﺎﻣﻴﻨﺎت واﻟﻤﻌﺎدن‬
‫ﻓﻴﺘﺎﻣﻴﻦ ج‬
‫ﻛﺎﻟﺴﻴﻮم‬
‫ﻛﻮﻟﻴﻜﺎﻟﺴﻴﻔﻴﺮول]ﻣﻼﺣﻈﺔ ‪[53‬‬

‫إرﻏﻮﻛﺎﻟﺴﻴﻔﻴﺮول‬
‫اﻟﻴﻮد‬
‫ﻧﻴﻜﻮﺗﻴﻨﺎﻣﻴﺪ‬
‫ﺑﻴﺮﻳﺪوﻛﺴﻴﻦ‬
‫رﺗﻴﻨﻮل‬
‫ﻓﻴﺘﺎﻣﻴﻦ ب‪2‬‬
‫ﻓﻠﻮرﻳﺪ اﻟﺼﻮدﻳﻮم‬
‫ﻓﻴﺘﺎﻣﻴﻦ ب‪1‬‬
‫اﻟﻜﺎﻟﺴﻴﻮم‪α‬‬ ‫ﻏﻠﻮﻛﻮﻧﺎت‬
‫أدوﻳﺔ اﻷﻧﻒ واﻷﻧﻒ واﻷذن واﻟﺤﻨﺠﺮة‬
‫ﻓﻲ اﻷﻃﻔﺎل‬
‫ﺣﻤﺾ اﻷﺳﻴﺘﻴﻚ‬
‫ﺑﻴﻮدﻳﺴﻮﻧﻴﺪ‬
‫ﺳﻴﺒﺮوﻓﻠﻮﻛﺴﺎﺳﻴﻦ‬
‫زاﻳﻠﻮﻣﻴﺘﺎزوﻟﻴﻦ‬

‫أدوﻳﺔ ﺧﺎﺻﺔ ﺑﺎﻟﺮﻋﺎﻳﺔ ﺣﺪﻳﺜﻲ اﻟﻮﻻدة‬

‫اﻟﻮﻻدة‬
‫ِ‬ ‫ﻟﺤﺪﻳﺚ‬ ‫ﻌﻄﻰ‬‫ﺗ‬‫ُ‬ ‫أدوﻳﺔ‬

‫ﺳﻴﺘﺮات اﻟﻜﺎﻓﻴﻴﻦ‬
‫ﻛﻠﻮرﻫﻴﻜﺴﻴﺪﻳﻦ‬
‫إﻳﺒﻮﺑﺮوﻓﻴﻦ‪α‬‬

‫‪αE‬‬ ‫ﺑﺮوﺳﺘﺎﻏﻼﻧﺪﻳﻦ‬
‫ﺑﺮوﺳﺘﺎﻏﻼﻧﺪﻳﻦ ‪E1‬‬
‫ﺑﺮوﺳﺘﺎﻏﻼﻧﺪﻳﻦ ‪E2‬‬
 ‫ﺑﺎﻟﺴﻄﺢ‪α‬‬ ‫ﻓﺎﻋﻞ‬

‫أدوﻳﺔ ُﺗﻌﻄﻰ ﻟﻸم‬

‫دﻳﻜﺴﺎﻣﻴﺘﺎزون‬

‫أدوﻳﺔ أﻣﺮاض اﻟﻤﻔﺎﺻﻞ‬

‫ﻟﻌﻼج اﻟﻨﻘﺮس‬
‫ِ‬ ‫أدوﻳﺔ ﺗﺴﺘﺨﺪم‬

‫أﻟﻮﺑﻴﻮرﻳﻨﻮل‬

‫ﻋﻮاﻣﻞ ﻣُ ﻌﺪﻟﺔ ﻟﻠﻤﺮض ُﺗﺴﺘﺨﺪم ﻓﻲ‬

‫اﻻﺿﻄﺮاﺑﺎت اﻟﺮوﻣﺎﺗﻮﻳﺪﻳﺔ‬

‫ﻛﻠﻮروﻛﻴﻦ‬
‫آزاﺛﻴﻮﺑﺮﻳﻦ‪α‬‬

‫ﻛﻠﻮروﻛﻮﻳﻦ‪α‬‬ ‫ﻫﻴﺪروﻛﺴﻲ‬
‫ﻣﻴﺜﻮﺗﺮﻛﺴﻴﺖ‪α‬‬

‫ﺑﻨﻴﺴﻴﻼﻣﻴﻦ‪α‬‬
 ‫ﺳﻠﻔﺎﺳﺎﻻزﻳﻦ‪α‬‬

‫أﻣﺮاض ﻣﻔﺎﺻﻞ اﻻ ْﺣﺪاث‬

‫أﺳﺒﺮﻳﻦ]ﻣﻼﺣﻈﺔ ‪[54‬‬

‫ﻣﻼﺣﻈﺎت‬
‫^ ُﺗﺸﻴﺮ ‪ α‬أن اﻟﺪواء ﻣﻮﺟﻮد ﺿﻤﻦ اﻟﻘﺎﺋﻤﺔ اﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻟﺘﺸﺨﻴﺺ ﺧﺎص أو‬
‫ٍ‬ ‫ﻓﻘﻂ‪ .‬ﺗﺤﺘﺎج ﻫﺬه اﻟﻌﻨﺎﺻﺮ‬
‫ﺗﺪرﻳﺐ ﺧﺎص‪ً ،‬‬
‫أﻳﻀﺎ ﻳُ ﻤﻜﻦ أن ﻳُ ﻮﺿﻊ‬ ‫ٍ‬ ‫ﻣﺮاﻗﺒﺔ أو‬
‫ٍ‬
‫ارﺗﻔﺎع ﺗﻜﻠﻔﺘﻪ أو‬
‫ِ‬ ‫ﺑﻨﺎء ﻋﻠﻰ‬
‫ﺿﻤﻦ اﻟﻘﺎﺋﻤﺔ اﻟﺘﻜﻤﻴﻠﻴﺔ ً‬
‫ﻟﻠﻔﺎﺋﺪة]‪[4‬‬ ‫ﻗﻠﺔ ﻧﺴﺒﺔ اﻟﺘﻜﻠﻔﺔ‬
‫‪ .1‬ﻗﺪ ﻳُ ﺴﺘﺨﺪم اﻟﺜﻴﻮﺑﻨﺘﺎل ﻛﺒﺪﻳﻞ اﻋﺘﻤﺎدً ا ﻋﻠﻰ‬
‫اﻟﺘﻮاﻓﺮ واﻟﻜُﻠﻔﺔ‪.‬‬
‫ﻛﻤﻀﺎد ﻟﻼﻟﺘﻬﺎﺑﺎت؛‬
‫ٍ‬ ‫‪ .2‬ﻏﻴﺮ ُﻣﻮﺻﻰ ِﺑﻪ ﻟﻼﺳﺘﺨﺪام‬
‫ﺑﺴﺒﺐ ﻋﺪم ﺛﺒﺎت ﻓﺎﺋﺪﺗﻪ ﻓﻲ ﻫﺬا اﻟﻐﺮض‬
‫ِ‬
‫‪ .3‬اﻟﺒﺪاﺋﻞ ﺗﻘﺘﺼﺮ ﻋﻠﻰ اﻟﻬﻴﺪروﻣﻮرﻓﻮن‬
‫واﻷوﻛﺴﻴﻜﻮدون‬
 ‫‪ .4‬ﻗﺪ ﻳﻜﻮن ﻫﻨﺎك دو ٌر ﻟﻤﻀﺎدات اﻟﻬﻴﺴﺘﺎﻣﻴﻦ‬
‫ﻟﺪواع ُﻣﺤﺪودة‪.‬‬
‫ٍ‬ ‫اﻟﻤﻬﺪﺋﺔ‬
‫ُ‬
‫‪ .5‬ﻟﻼﺳﺘﺨﺪام ﻓﻲ اﻹرﺟﺎج وﻣﺎ ﻗﺒﻞ اﻹرﺟﺎج‪،‬‬
‫وﻟﻴﺲ ﻟﻼﺿﻄﺮاﺑﺎت اﻻﺧﺘﻼﺟﻴﺔ اﻻﺧﺮى‪.‬‬
‫َ‬
‫‪ .6‬ﻟﻠﻮﻗﺎﻳﺔ اﻟﺠﺮاﺣﻴﺔ‬
‫‪َ .7‬وﺿﻌﺖ ﻓﻲ اﻟﻘﺎﺋﻤﺔ ﻟﻌﻼج اﻟﺴﻴﻼن اﻟﺸﺮﺟﻲ‬
‫اﻟﺘﻨﺎﺳﻠﻲ ﻏﻴﺮ اﻟﻤﺼﺤﻮب ﺑﻤﻀﺎﻋﻔﺎت ﺑﺠﺮﻋﺔ‬
‫ﻃﺒﻴﻌﻴﺔ وﺣﻴﺪة‪.‬‬
‫‪ .8‬ﺿﻤﻦ اﻟﺠﻴﻞ اﻟﺜﺎﻟﺚ ﻟﻠﺴﻴﻔﺎﻟﻮﺳﺒﻮرﻳﻦ وﻳُ ﺴﺘﺨﺪم‬
‫ﻓﻲ ﺣﺪﻳﺜﻲ اﻟﻮﻻدة ﻓﻲ اﻟﻤﺴﺘﺸﻔﻰ‪.‬‬
‫‪ .9‬ﻻ ﻳُ ﻌﻄﻲ ﻣﻊ اﻟﻜﺎﻟﺴﻴﻮم وﻳُ ﺘﺠﻨﺐ اﺳﺘﺨﺪاﻣﻪ ﻣﻊ‬
‫اﻟﻤﺼﺎﺑﻴﻦ ﺑﻔﺮط ﺑﻴﻠﻴﺮوﺑﻴﻦ اﻟﺪم‪.‬‬
‫اﻟﺮﺿﻊ ُ‬
‫ُ‬
‫‪ .10‬ﻻ ﻳُ ﻨﺼﺢ ﺑﺎﺳﺘﻌﻤﺎل اﻟﺒﺮوﻛﺎﻳﻦ ﺑﻨﺰﻳﻞ ﺑﻨﺴﻴﻠﻠﻴﻦ‬
‫ﻛﻌﻼج أوﻟﻲ ﻓﻲ إﻧﺘﺎن ﺣﺪﻳﺜﻲ اﻟﻮﻻدة ﻣﺎ ﻋﺪا‬
‫ٍ‬
‫ﻓﻲ ﻇﺮوف ارﺗﻔﺎع ﻣﻌﺪل وﻓﻴﺎت ﺣﺪﻳﺜﻲ‬
‫اﻟﻮﻻدة‪ ،‬وﻳﺠﺐ أن ﻳُ ﻌﻄﻲ ﺑﻮاﺳﻄﺔ ﻣﻤﺎرﺳﻴﻦ‬
 ‫ﺻﺤﻴﻴﻦ ُﻣﺪرﺑﻴﻦ ﻓﻲ اﻟﺤﺎﻻت اﻟﺘﻲ ﻻ ﻳُ ﻤﻜﻦ‬
‫ﺗﺤﻘﻴﻖ اﻟﺮﻋﺎﻳﺔ ﻓﻲ اﻟﻤﺴﺘﺸﻔﻴﺎت‪.‬‬
‫‪ُ .11‬وﺿﻊ ﻓﻲ اﻟﻘﺎﺋﻤﺔ ﻟﻌﻼج اﻟﻌﺪوى اﻟﺤﺎﺻﻠﺔ ﻓﻲ‬
‫واﻟﻤﻬﺪدة ﻟﻠﺤﻴﺎة ﺑﺴﺒﺐ اﺷﺘﺒﺎه أو‬
‫اﻟﻤﺴﺘﺸﻔﻰ ُ‬
‫إﺛﺒﺎت وﺟﻮد ﻋﺪوى ﻣﻘﺎوﻣﺔ ﻟﻸدوﻳﺔ اﻟﻤﺘﻌﺪدة‪.‬‬
‫‪َ .12‬وﺿﻊ ﻓﻲ اﻟﻘﺎﺋﻤﺔ ﻟﻌﻼج اﻟﻤﺘﺪﺛﺮة اﻟﺘﺮاﺧﻮﻣﻴﺔ‬
‫واﻟﺘﺮاﺧﻮﻣﺎ ﺑﺠﺮﻋﺔ ﻃﺒﻴﻌﻴﺔ وﺣﻴﺪة‪.‬‬
‫‪ .13‬ﻟﻼﺳﺘﺨﺪام ﻓﻲ ﻧﻈﻢ ﻋﻼﺟﻴﺔ ُﻣﺮﻛﺒﺔ ﻟﻠﻘﻀﺎء ﻋﻠﻰ‬
‫اﻟﻤﻠﻮﻳﺔ اﻟﺒﻮاﺑﻴﺔ ﻓﻲ اﻟﺒﺎﻟﻐﻴﻦ‪.‬‬
‫اﻟﻤﺼﺎﺑﻴﻦ ﺑﻔﻴﺮوس‬
‫‪ .14‬ﻟﻼﺳﺘﺨﺪام ﻓﻲ اﻟﻤﺮﺿﻰ ُ‬
‫اﻟﻤﺘﻠﻘﻴﻦ ﻟﻤﺜﺒﻄﺎت‬
‫ﻧﻘﺺ اﻟﻤﻨﺎﻋﺔ اﻟﺒﺸﺮﻳﺔ ُ‬
‫اﻟﺒﺮوﺗﻴﺎز‪.‬‬
‫‪ .15‬ﻟﻌﻼج ﻋﺪوى اﻟﺴﻞ اﻟﻜﺎﻣﻨﺔ ﻓﻘﻂ‪.‬‬
‫ً‬
‫ﺑﺪﻳﻼ ﻟﻪ‪.‬‬ ‫‪ .16‬ﻗﺪ ﻳﻜﻮن اﻟﺘﻴﺮﻳﺰﻳﺪون‬
‫ً‬
‫ﺑﺪﻳﻼ ﻟﻪ‪.‬‬ ‫‪ .17‬ﻗﺪ ﻳﻜﻮن اﻟﺒﺮوﺗﻴﻮﻧﺎﻣﻴﺪ‬
‫‪ .18‬ﻗﺪ ﻳﻜﻮن اﻷوﻓﻠﻮﻛﺴﺎﺳﻴﻦ واﻟﻤﻮﻛﺴﻴﻔﻠﻮﻛﺴﺎﺳﻴﻦ‬
‫ً‬
‫ﺑﺪﻳﻼ ﻟﻪ‪ ،‬وﻫﺬا ﻳﻌﺘﻤﺪ ﻋﻠﻰ اﻟﺘﻮاﻓﺮ وإﻣﻜﺎﻧﻴﺎت‬
‫اﻟﺒﺮﻧﺎﻣﺞ‪.‬‬
‫‪ FTC .19‬ﻫﻮ ﺑﺪﻳﻞ ُﻣﻨﺎﺳﺐ ل‪ ،3TC‬وﻫﺬا ﻳﻌﺘﻤﺪ‬
‫ﻋﻠﻰ اﻟﻤﻌﺮﻓﺔ ﺑﻌﻠﻢ اﻷدوﻳﺔ وأﻧﻤﺎط اﻟﻤﻘﺎوﻣﺔ‬
‫واﻟﺘﺠﺎرب اﻟﺴﺮﻳﺮﻳﺔ ﻟﻤﻀﺎدات اﻟﻔﻴﺮوﺳﺎت‬
‫اﻟﻘﻬﻘﺮﻳﺔ‪.‬‬
‫‪ .20‬ﻳُ ﺴﺘﺨﺪم ﻟﻌﻼج اﻟﺤﻤﻰ اﻟﻔﻴﺮوﺳﻴﺔ اﻟﻨﺰﻓﻴﺔ‬
‫ﺑﺎﻻﺷﺘﺮاك ﻣﻊ اﻹﻧﺘﺮﻓﻴﺮوﻧﺎت اﻟﻤﻀﺎف إﻟﻴﻬﺎ ﺑﻮﻟﻲ‬
‫إﻳﺜﻴﻠﻴﻦ ﺟﻠﻴﻜﻮل‪ ،‬ﺑﻬﺪف ﻋﻼج اﻟﺘﻬﺎب اﻟﻜﺒﺪ‬
‫ﺳﻲ‪.‬‬
‫‪ .21‬ﻳُ ﺴﺘﺨﺪم ﻓﻲ اﻷﻣﺮاض اﻟﺸﺪﻳﺪة أو اﻟﻤﻌﻘﺪة‬
‫ﺑﺴﺒﺐ اﺷﺘﺒﺎه أو ﺗﺄﻛﺪ ﺑﻌﺪوى ﻓﻴﺮوﺳﺎت‬
‫اﻹﻧﻔﻠﻮﻧﺰا‪ ،‬وذﻟﻚ ً‬
‫وﻓﻘﺎ ﻟﻠﻤﺒﺎدئ اﻟﺘﻮﺟﻴﻬﻴﺔ‬
‫اﻟﻌﻼﺟﻴﺔ ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‪.‬‬
‫‪ .22‬ﻟﻌﻼج اﻟﺘﻬﺎب اﻟﻜﺒﺪ ﺳﻲ )ج(‪ ،‬وﺗﻜﻮن ﻓﻲ ﺗﺮﻛﻴﺒﺔ‬
‫ﻣﻊ إﻧﺘﺮﻓﻴﺮوﻧﺎت ﻣﻀﺎف إﻟﻴﻬﺎ ﺑﻮﻟﻲ إﻳﺜﻴﻠﻴﻦ‬
‫ﺟﻠﻴﻜﻮل أو ﻣﻀﺎدات ﻓﻴﺮوﺳﻴﺔ ﻣﺒﺎﺷﺮة‬
‫اﻟﻤﻔﻌﻮل‪.‬‬
‫‪ُ .23‬ﺗﺴﺘﺨﺪم ﻓﻲ ﺗﺮﻛﻴﺒﺔ ﻣﻊ اﻟﺮﻳﺒﺎﻓﻴﺮﻳﻦ‪.‬‬
‫‪ .24‬ﻳُ ﺴﺘﺨﺪم ﻓﻲ ﺗﺮﻛﻴﺒﺔ ﻣﻊ اﻷرﺗﻴﺴﻮﻧﺎت ‪ 50‬ﻣﻠﻐﻢ‪.‬‬
‫‪ .25‬ﻳُ ﺴﺘﺨﺪم ﻹدارة ﺣﺎﻻت اﻟﻤﻼرﻳﺎ اﻟﺸﺪﻳﺪة‪.‬‬
‫‪ .26‬ﻻ ﻳُ ﻨﺼﺢ ﺑﻪ ﻓﻲ اﻷﺛﻠﻮث اﻷول ﻣﻦ اﻟﺤﻤﻞ أو ﻓﻲ‬
‫اﻷﻃﻔﺎل اﻟﻮزﻧﻬﻢ أﻗﻞ ﻣﻦ ‪ 5‬ﻛﺠﻢ‪.‬‬
‫‪ .27‬ﻳُ ﺴﺘﺨﺪم ﻓﻲ ﺗﺮﻛﻴﺒﺔ ﻣﻊ أﻣﻮﻳﺎﻛﻮﻳﻦ وﻣﻔﻠﻮﻛﻮﻳﻦ‬
‫أو ﺳﻠﻔﺎدوﻛﺴﻴﻦ وﺑﻴﺮﻳﻤﻴﺜﺎﻣﻴﻦ‪.‬‬
‫‪ .28‬ﻳُ ﻤﻜﻦ اﺳﺘﻌﻤﺎل ﺑﻌﺾ اﻟﺒﺪاﺋﻞ‪ ،‬ﻓﺒﻌﺾ اﻟﺘﺮﻛﻴﺒﺎت‬
‫اﻟﺘﻲ ُﺗﻘﺪم اﻟﺠﺮﻋﺎت اﻟﻤﻄﻠﻮﺑﺔ ﻣﺜﻞ ‪ 150‬ﻣﻠﻐﻢ‬
‫أو ‪ 200‬ﻣﻠﻐﻢ )ﻣﺜﻞ اﻟﻬﻴﺪروﻛﻠﻮرﻳﺪ( ﻣﻊ ‪50‬‬
‫أرﺗﻴﺴﻮﻧﺎت ﻣﻠﻐﻢ‪.‬‬
 ‫‪ .29‬ﻳُ ﺴﺘﺨﺪم ﻓﻘﻂ ﻟﻌﻼج ﻋﺪوى اﻟﻤﺘﺼﻮرة‬
‫اﻟﻨﺸﻴﻄﺔ‪.‬‬
‫‪ .30‬ﻳُ ﺴﺘﺨﺪم ﻓﻘﻂ ﻓﻲ ﺗﺮﻛﻴﺒﺔ ﻣﻊ اﻟﻜﻴﻨﻴﻦ‪.‬‬
‫‪ .31‬ﻳُ ﺴﺘﺨﺪم ﻓﻘﻂ ﻟﺘﺤﻘﻴﻖ اﻟﻌﻼج اﻟﺠﺬري ﻓﻲ‬
‫ﻋﺪوى اﻟﻤﺘﺼﻮرة اﻟﻨﺸﻴﻄﺔ واﻟﻤﺘﺼﻮرة‬
‫اﻟﺒﻴﻀﻮﻳﺔ‪ ،‬وﻳُ ﻌﻄﻰ ﻟﻤﺪة ‪ 14‬ﻳﻮم‪.‬‬
‫‪ .32‬ﻳُ ﺴﺘﺨﺪم ﻓﻘﻂ ﻹدارة ﺣﺎﻻت اﻟﻤﻼرﻳﺎ اﻟﺸﺪﻳﺪة‪،‬‬
‫وﻳﺠﺐ أن ﻳُ ﺴﺘﺨﺪم ﻓﻲ ﺗﺮﻛﻴﺒﺔ ﻣﻊ‬
‫اﻟﺪوﻛﺴﻴﺴﺎﻳﻜﻠﻴﻦ‪.‬‬
‫‪ .33‬ﻳُ ﺴﺘﺨﺪم ﻓﻘﻂ ﻓﻲ ﺗﺮﻛﻴﺒﺔ ﻣﻊ أرﺗﻴﺴﻮﻧﺎت ‪50‬‬
‫ﻣﻠﻐﻢ‪.‬‬
‫‪ .34‬ﻳُ ﺴﺘﺨﺪم ﻓﻲ ﻣﻨﺎﻃﻖ أﻣﺮﻳﻜﺎ اﻟﻮﺳﻄﻰ ﻟﻌﻼج‬
‫اﻟﻤﺘﺼﻮرة اﻟﻨﺸﻴﻄﺔ‪.‬‬
‫‪ .35‬ﻳُ ﺴﺘﺨﺪم ﻓﻘﻂ ﻓﻲ ﺗﺮﻛﻴﺒﺔ ﻣﻊ اﻟﻜﻠﻮروﻛﻴﻦ‪.‬‬
‫‪ .36‬ﻳُ ﺴﺘﺨﺪم ﻟﻌﻼج ﻋﺪوى اﻟﻤﺜﻘﺒﻴﺔ اﻟﺒﺮوﺳﻴﺔ‬
‫اﻟﻐﺎﻣﺒﻴﺔ‪.‬‬
‫‪ .37‬ﻳُ ﺴﺘﺨﺪم ﻟﻠﻤﺮﺣﻠﺔ اﻷوﻟﻰ ﻟﻌﻼج ﻋﺪوى اﻟﻤﺜﻘﺒﻴﺔ‬
‫اﻟﺒﺮوﺳﻴﺔ اﻟﺮودﻳﺴﻴﺔ‪.‬‬
‫‪ .38‬ﻳُ ﺴﺘﺨﺪم ﻟﻌﻼج ﻋﺪوى اﻟﻤﺜﻘﺒﻴﺔ اﻟﺒﺮوﺳﻴﺔ‬
‫اﻟﻐﺎﻣﺒﻴﺔ‪.‬‬
‫‪ .39‬ﻳُ ﺴﺘﺨﺪم ﻓﻘﻂ ﻓﻲ ﺗﺮﻛﻴﺒﺔ ﻣﻊ اﻹﻓﻠﻮرﻧﻴﺘﻴﻦ‬
‫ﻟﻌﻼج ﻋﺪوى اﻟﻤﺜﻘﺒﻴﺔ اﻟﺒﺮوﺳﻴﺔ اﻟﻐﺎﻣﺒﻴﺔ‪.‬‬
‫‪ .40‬ﻳُ ﻤﻜﻦ أن ﻳﻜﻮن اﻟﺸﻜﻞ َ‬
‫اﻟﻔﻤﻮي ﻟﻠﺪﻳﻔﻴﺮوﻛﺴﺎﻣﻴﻦ‬
‫ﻛﺒﺪﻳﻞ‪ ،‬وﻫﺬا ﻳﻌﺘﻤﺪ ﻋﻠﻰ اﻟﺘﻜﻠﻔﺔ واﻟﺘﻮاﻓﺮ‪.‬‬
‫‪ .41‬ﻫﻮ ﺑﻮﻟﻴﺠﻠﻴﻦ‪ ،‬ﻣﺤﻠﻮل ﻗﺎﺑﻞ ﻟﻠﺤﻖ‪ ،‬ﻣﻜﺎﻓﺌﺘﻪ‬
‫ﺗﺴﺎوي ‪.%3.5‬‬
‫‪ .42‬ﺗﺘﻀﻤﻦ ﻣﻴﺘﻮﺑﺮوﻟﻮل وﻛﺎرﻓﻴﺪﻳﻠﻮل ﻛﺒﺪاﺋﻞ‪.‬‬
‫‪ُ .43‬وﺿﻊ اﻟﻬﻴﺪراﻻزﻳﻦ ﻓﻲ اﻟﻘﺎﺋﻤﺔ ﻻﺳﺘﺨﺪاﻣﻪ ﻓﻲ‬
‫إدارة اﻟﺤﺎﻻت اﻟﺤﺎدة ﻓﻘﻂ ﻣﻦ ارﺗﻔﺎع ﺿﻐﻂ‬
‫اﻟﺤﻤﻞ‪ ،‬وﻻ ﻳُ ﻮﺻﻰ‬
‫اﻟﺪم اﻟﺸﺪﻳﺪ اﻟﻨﺎﺟﻢ ﻋﻦ َ‬
‫ﺑﺎﺳﺘﺨﺪاﻣﻪ ﻓﻲ ﻋﻼج ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم‬
 ‫ﻧﻈﺮا ﻟﺘﻮاﻓﺮ ﻋﺪد ﻣﻦ اﻷدﻟﺔ ﻋﻠﻰ‬
‫اﻷﺳﺎﺳﻲ ً‬
‫ﻓﻌﺎﻟﻴﺔ وﺳﻼﻣﺔ اﻷدوﻳﺔ اﻷﺧﺮى‪.‬‬
‫‪ُ .44‬وﺿﻊ اﻟﻤﺜﻴﻠﺪوﺑﺎ ﻓﻲ اﻟﻘﺎﺋﻤﺔ ﻻﺳﺘﺨﺪاﻣﻪ ﻓﻲ‬
‫إدارة اﻟﺤﺎﻻت اﻟﺤﺎدة ﻓﻘﻂ ﻣﻦ ارﺗﻔﺎع ﺿﻐﻂ‬
‫اﻟﺤﻤﻞ‪ ،‬وﻻ ﻳُ ﻮﺻﻰ‬
‫اﻟﺪم اﻟﺸﺪﻳﺪ اﻟﻨﺎﺟﻢ ﻋﻦ َ‬
‫ﺑﺎﺳﺘﺨﺪاﻣﻪ ﻓﻲ ﻋﻼج ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم‬
‫ﻧﻈﺮا ﻟﺘﻮاﻓﺮ ﻋﺪد ﻣﻦ اﻷدﻟﺔ ﻋﻠﻰ‬
‫اﻷﺳﺎﺳﻲ ً‬
‫ﻓﻌﺎﻟﻴﺔ وﺳﻼﻣﺔ اﻷدوﻳﺔ اﻷﺧﺮى‪.‬‬
‫‪ُ .45‬ﺗﺴﺘﺨﺪم ﻓﻲ اﻟﻤﺮﺿﻰ اﻟﻤﻌﺮﺿﻴﻦ ﻟﻠﺨﻄﺮ‪.‬‬
‫‪ .46‬ﻓﻲ اﻹﺳﻬﺎل اﻟﺤﺎد ﻳﻨﺒﻐﻲ اﺳﺘﻌﻤﺎل ﻛﺒﺮﻳﺘﺎت‬
‫ﻛﻤﺴﺎﻋﺪ ﻷﻣﻼح اﻹﻣﻬﺎء اﻟﻔﻤﻮي‬
‫اﻟﺰﻧﻚ ُ‬
‫‪ .47‬اﻟﻐﻠﻴﺒﻴﻨﻜﻼﻣﻴﺪ ﻏﻴﺮ ُﻣﻨﺎﺳﺒﺔ ﻟﻸﺷﺨﺎص ﻓﻮق ‪60‬‬
‫ﺳﻨﺔ‪.‬‬
‫ﻣﺤﻠﻴﺎ‬
‫ً‬ ‫‪ .48‬ﻧﻮع دﻗﻴﻖ ﻳﺘﻢ اﻟﺘﻌﺮﻳﻒ ﺑﻪ‬
‫اﻟﺴﻜﺎن اﻟﻤﻌﺮﺿﻴﻦ َ‬
‫ﻟﻠﺨﻄﺮ‪.‬‬ ‫‪ .49‬ﻳُ ﻮﺻﻰ ﺑﻪ ﻟﺒﻌﺾ ُ‬
‫‪ .50‬ﻳُ ﻮﺻﻰ ﺑﻪ ﻟﺒﻌﺾ اﻟﻤﻨﺎﻃﻖ‪.‬‬
 ‫‪ .51‬أو ﻫﻮﻣﺎﺗﺮوﺑﻴﻦ )ﻫﻴﺪروﺑﺮوﻣﻴﺪ( أو‬
‫ﺳﻜﻠﻮﺑﻨﺘﻮﻻت )ﻫﻴﺪروﻛﻠﻮرﻳﺪ(‪.‬‬
‫‪ .52‬ﻳﺤﺘﺎج ﻹﺷﺮاف ِﻃﺒﻲ وﺛﻴﻖ‪.‬‬
‫‪ .53‬ﻳُ ﻤﻜﻦ اﺳﺘﺨﺪام اﻹرﻏﻮﻛﺎﻟﺴﻴﻔﻴﺮول ﻛﺒﺪﻳﻞ‪.‬‬
‫‪ .54‬ﻟﻼﺳﺘﺨﺪام ﻓﻲ اﻟﺤﻤﻰ اﻟﺮوﻣﺎﺗﻴﺰﻣﻴﺔ واﻻﻟﺘﻬﺎب‬
‫اﻟﻤﻔﺼﻠﻲ اﻟﻴﻔﻌﻲ وداء ﻛﺎواﺳﺎﻛﻲ‬

‫اﻟﻤﺮاﺟﻊ‬
‫ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ ‪ -‬ﻗﻮاﺋﻢ اﻷدوﻳﺔ" ‪1.‬‬
‫‪".‬اﻷﺳﺎﺳﻴﺔ اﻟﻨﻤﻮذﺟﻴﺔ ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‬
‫ﻣﺆرﺷﻒ ﻣﻦ اﻷﺻﻞ ﻓﻲ ‪ 21‬أﺑﺮﻳﻞ ‪WHO.‬‬
‫‪ .2019.‬اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ ‪ 2‬ﻳﻨﺎﻳﺮ ‪2018‬‬
‫‪2. "Essential medicines". World Health‬‬
‫ﻣﺆرﺷﻒ ﻣﻦ اﻷﺻﻞ ﻓﻲ ‪Organization. 18‬‬
‫أﺑﺮﻳﻞ ‪ .2019‬اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ ‪ 19‬ﻳﻨﺎﻳﺮ‬
‫‪2017.‬‬
3. "The WHO Essential Medicines List
(EML): 30th anniversary". World
Health Organization. ‫ﻣﺆرﺷﻒ ﻣﻦ اﻷﺻﻞ‬
26 ‫ اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ‬.2019 ‫ ﻣﺎرس‬22 ‫ﻓﻲ‬
2016 ‫ﻳﻮﻧﻴﻮ‬.
4. "19th WHO Model List of Essential
Medicines" (pdf). who.int. World
Health Organization. .2015 ‫أﺑﺮﻳﻞ‬
‫ﺻﻔﺤﺔ‬ Annex 1. ‫ ﻳﻨﺎﻳﺮ‬17 ‫اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ‬
2017.
5. Bansal، D‫ ؛‬Purohit، VK (2013 ‫)ﻳﻨﺎﻳﺮ‬.
"Accessibility and use of essential
medicines in health care: Current
progress and challenges in India.".
Journal of Pharmacology &
Pharmacotherapeutics. 4 (1): 13–18.
 PMC 3643337 . PMID  23662019.
doi: 10.4103/0976-500X.107642.
6. "The Selection and Use of Essential
Medicines - WHO Technical Report
Series، No. 920: 5. Reviews of
sections of the Model List: 5.2
Review of core versus
complementary listing of medicines".
apps.who.int. 2003. ‫ﻣﺆرﺷﻒ ﻣﻦ اﻷﺻﻞ‬
6 ‫ اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ‬.2018 ‫ ﻣﺎﻳﻮ‬19 ‫ﻓﻲ‬
2017 ‫ﻣﺎرس‬.
7. Beall، Reed (2016). "Patents and the
WHO Model List of Essential
Medicines (18th Edition): Clarifying
the Debate on IP and Access" (PDF).
 WIPO. ‫( ﻣﺆرﺷﻒ ﻣﻦ اﻷﺻﻞ‬PDF) 11 ‫ﻓﻲ‬
2017 ‫ ﻣﺎﻳﻮ‬3 ‫ اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ‬.2019 ‫ﻣﺎﻳﻮ‬.
8. Wirtz، VJ‫ ؛‬Hogerzeil، HV‫ ؛‬Gray، AL‫؛‬
Bigdeli، M‫ ؛‬de Joncheere، CP.‫؛ وآﺧﺮون‬
2017 ‫ ﻳﻨﺎﻳﺮ‬28)). "Essential medicines
for universal health coverage". The
Lancet. 389 (10067): 403–476.
PMID  27832874.
doi: 10.1016/S0140-6736(16)31599-
9.
9. "WHO Model Lists of Essential
Medicines". World Health
Organization. 1 ‫ﻣﺆرﺷﻒ ﻣﻦ اﻷﺻﻞ ﻓﻲ‬
‫ ﻳﻨﺎﻳﺮ‬17 ‫ اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ‬.2019 ‫ﻣﺎﻳﻮ‬
2017.
10. Prakash، B‫ ؛‬Nadig، P‫ ؛‬Nayak، A
(2016). "Rational Prescription for a
Dermatologist.". Indian Journal of
Dermatology. 61 (1): 32–38.
PMC 4763692 . PMID  26955092.
doi: 10.4103/0019-5154.174017.
11. "WHO Model List of Essential
Medicines 20th List" (PDF). ‫ﻣﺎرس‬
‫ ﻣﺆرﺷﻒ ﻣﻦ اﻷﺻﻞ‬.2017 (PDF) 25 ‫ﻓﻲ‬
‫ ﻳﻮﻧﻴﻮ‬8 ‫ اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ‬.2017 ‫أﻛﺘﻮﺑﺮ‬
2017.
12. "Essential Medicines List and WHO
Model Formulary". World Health
Organization. 19 ‫ﻣﺆرﺷﻒ ﻣﻦ اﻷﺻﻞ ﻓﻲ‬
2018 ‫ ﻣﺎﻳﻮ‬5 ‫ اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ‬.2019 ‫أﺑﺮﻳﻞ‬.
13. "WHO Model List of Essential
Medicines for Children 6th List" (PDF).
who.int. World Health Organization.
‫ ﻣﺆرﺷﻒ ﻣﻦ اﻷﺻﻞ‬.2017 ‫( أﻏﺴﻄﺲ‬PDF)
11 ‫ اﻃﻠﻊ ﻋﻠﻴﻪ ﺑﺘﺎرﻳﺦ‬.2019 ‫ ﻣﺎرس‬22 ‫ﻓﻲ‬
2018 ‫أﺑﺮﻳﻞ‬.
14. Rose، K‫ ؛‬Anker، JNVd (2010). Guide
to Paediatric Drug Development and
Clinical Research (‫)ﺑﺎﻟﻠﻐﺔ اﻹﻧﺠﻠﻴﺰﻳﺔ‬.
Karger Medical and Scientific
Publishers. 42 ‫ﺻﻔﺤﺔ‬.
ISBN 9783805593625.
15. Seyberth، HW‫ ؛‬Rane، A‫ ؛‬Schwab، M
(2011). Pediatric Clinical
Pharmacology (‫)ﺑﺎﻟﻠﻐﺔ اﻹﻧﺠﻠﻴﺰﻳﺔ‬.
 ‫‪Springer Science & Business Media.‬‬
‫‪. ISBN 9783642201950.‬ﺻﻔﺤﺔ‪358 ‬‬
‫‪). "Essential‬ﻓﺒﺮاﻳﺮ ‪16. Kalle، H (9 2017‬‬
‫‪Medicines for Children". Clinical‬‬
‫‪Pharmacology & Therapeutics. 101:‬‬
‫‪718–720. PMID  28182281.‬‬
‫‪doi: 10.1002/cpt.661.‬‬

‫ﻗﺮاءات أﺧﺮى‬
‫اﻟﻮﺻﻔﺎت اﻟﻨﻤﻮذﺟﻴﺔ ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‬
‫‪ .(PDF) 2008‬ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‪.2009 .‬‬
‫‪.ISBN 9789241547659‬‬
‫اﺧﺘﻴﺎر واﺳﺘﺨﺪام اﻷدوﻳﺔ اﻷﺳﺎﺳﻴﺔ‪ :‬اﻟﺘﻘﺮﻳﺮ‬
‫اﻟﻌﺸﺮﻳﻦ ﻟﻠﺠﻨﺔ ﺧﺒﺮاء ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ ﻟﻌﺎم‬
‫‪) 2015‬ﺗﺘﻀﻤﻦ اﻟﻨﺴﺨﺔ اﻟﺘﺎﺳﻌﺔ ﻋﺸﺮ ﻣﻦ ﻗﺎﺋﻤﺔ‬
‫اﻷدوﻳﺔ اﻷﺳﺎﺳﻴﺔ اﻟﻨﻤﻮذﺟﻴﺔ ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ‬
‫اﻟﻌﺎﻟﻤﻴﺔ واﻟﻨﺴﺨﺔ اﻟﺨﺎﻣﺴﺔ ﻟﻘﺎﺋﻤﺔ اﻷدوﻳﺔ‬
 ‫اﻷﺳﺎﺳﻴﺔ اﻟﻨﻤﻮذﺟﻴﺔ ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‬
‫اﻟﺨﺎﺻﺔ ﺑﺎﻷﻃﻔﺎل(‪ .(PDF) .‬ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ‬
‫اﻟﻌﺎﻟﻤﻴﺔ‪.ISBN 9789240694941 .2015 .‬‬
‫ﺑﻮاﺑﺔ ﻃﺐ‬
‫ﺑﻮاﺑﺔ ﺻﻴﺪﻟﺔ‬
‫ﺑﻮاﺑﺔ اﻷﻣﻢ اﻟﻤﺘﺤﺪة‬
‫ﻓﻲ ﻛﻮﻣﻨﺰ ﺻﻮر وﻣﻠﻔﺎت ﻋﻦ‪ :‬ﻗﺎﺋﻤﺔ اﻷدوﻳﺔ‬
‫اﻷﺳﺎﺳﻴﺔ اﻟﻨﻤﻮذﺟﻴﺔ ﻟﻤﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ‬

‫ﻣﺠﻠﻮﺑﺔ ﻣﻦ "?‪https://ar.wikipedia.org/w/index.php‬‬
‫ﻗﺎﺋﻤﺔ_اﻷدوﻳﺔ_اﻷﺳﺎﺳﻴﺔ_اﻟﻨﻤﻮذﺟﻴﺔ_ﻟﻤﻨﻈﻤﺔ_اﻟﺼﺤﺔ_=‪title‬‬
‫‪&oldid=35615347‬اﻟﻌﺎﻟﻤﻴﺔ"‬

‫آﺧﺮ ﺗﻌﺪﻳﻞ ﺗﻢ ﻗﺒﻞ ‪ 3‬ﺷﻬﻮر ﺑﻮاﺳﻄﺔ ‪JarBot‬‬

‫اﻟﻤﺤﺘﻮى ﻣﺘﺎح وﻓﻖ ‪ CC BY-SA 3.0‬إن ﻟﻢ ﻳﺮد ﺧﻼف ذﻟﻚ‪.‬‬